AP578A - Quinoline derivatives. - Google Patents

Abstract

Nk3 receptor antagonists of formula (1): are useful in treating inter alia pulmonary disorders, cns disorders and neurodegenerative disorders

Description

The present invention relates to novel quinoline derivatives, processes for their preparation and their use in medicine.

The mammalian peptide Neurokinin Β (NKB) belongs to the Tachykinin (TK) peptide family which also include Substance P (SP) and Neurokinin A (NKA).

Pharmacological and molecular biological evidence has shown the existence of three subtypes of TK receptor (ΝΚμ NK₂ and NK₃) and NKB binds preferentially to the NK3 receptor althougn it also recognises the other two receptors with lower affinity (Maggi ci U . 1993, J. Auton. Pharmacol., 13, 23-93).

Selective peptidic NK3 receptor antagonists are known (Drapeau, 1990 Regul. t Pept., 31. i 25-135). and findings with peptidic NK₃ receptor agonists suggest that

NKB, by activating the NK3 receptor, has a key role in the modulation of neural input in airways, skin, spinal cord and nigro-striatal pathways (Myers and Undem, 1993, *

J.PhisioL, 470,665-679; Counture et al., 1993, Regul. Peptides, 46,426-429; _r

Mccarson and Krause, 1994, J. Neurosci., 14 (2), 712-720; Arenas et aL 1991. £

INevrosci., 11,2332-8).

However, the peptide-like nature of the known antagonists makes them likely to be too labile from a metabolic point of view to serve as practical therapeutic agerls.

We have now discovered a novel class of selective, non-peptide NK3 antagonists which are far more stable from a metabolic point of view than the known Cp peptidic NK3 receptor antagonists and are of potential therapeutic utility in treating pulmonary disorders (asthma, chronic obstructive pulmonary diseases -COPD-, ι 25 airway hyperreactivity, cough), skin disorders and itch (for example, atopic dermatitis and cutaneous wheal and flare), neurogenic inflammation and CNS disorders (Parkinson s disease, movement disorders, anxiety and psychosis). These disorders are referred to hereinafter as the Prioary Disorders.

The novel NK3 antagonists of the present invention are also of potential therapeutic SO utility in treating convulsive disorders (for example epilepsy), renal disorders, urinary incontinence, ocular inflammation, inflammatory pain, eating disorders {food intake inhibition}, allergic rhinitis, neurodegeneraiive disorders (for example Alzheimer's disease), psoriasis, Huntington's disease, and depression (hereinafter referred to as the Secondary Disorders).

^s According '0 (lie present invention there is provided a compound, ora solvate or suit there- T, of formula fl):

u /u/ctV

P?O95S

(D in which:

Ar is an optionally substituted phenyl, naphthyl or C5.7 cycloalkdienyl group, or an optionally substituted single or fused ring heterocyclic group, having aromatic character, containing from 5 to 12 ring atoms and comprising up to four heteroatoms in the or each ring selected from S, Ο, N;

R is linear or branched Cj.g alkyl, C3.7 cycloalkyl, ¢4.7 cycloalkylalkyl, optionally substituted phenyl or phenyl Cj.g alkyl, an optionally substituted five-membered heteroaromatic ring comprising up to four heteroatom selected from O and N, hydroxy Cialkyl, amino Cpg alkyl, alkylaminoalkyl, di alkylaminoalkyl, Ci_6 acylaminoalkyl, Cj.g alkoxyalkyl, C1.5 alkylcarbonyl, carboxy, Cj.g alkoxyxcarbonyl, Cj.g alkoxycarbonyl Cj.g alkyl, aminocarbonyl, C}_6 alkylaminocarbonyl, di alkylaminocarbonyl, halogeno Cj.g alkyl; or is a group -(CH2)p- when cyclized onto Ar, where p is 2 or 3.

Rj and R2, which may be the same or different, are independently hydrogen or Cj_6 linear or branched alkyl, or together form a -(CH2)n- group in which n represents 3,4, or 5; or Ri together with R forms a group -(CH2)q-, in which q is 2,3,4 or 5.

R3 and R4, which may be the same or different, are independently hydrogen, Ci-6 linear or branched alkyl, Ci_<> alkenyl, aryl, Cj_6 alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, Cj.g alkoxycarbonyl, trifluoromethyl, acyloxy, phthalimido, amino, mono- and di-Cpg alkylamino, -O(CH2)_r-NT2, in which r is 2,3, or 4 and T is hydrogen or Cj.g alkyl or it forms with the adjacent nitrogen a group

AP/P' 05/00745

V,

in which V and Vj are independently hydrogen or oxygen and u is 0,1 or 2; -O(CH2)s'OW2 in which s is 2,3, or 4 and W is hydrogen or Cj.g alkyl;

hydroxyalkyl, aminoalkyl, mono-or di-alkylarainoalkyl, acylamino,

AP.00578 alkyisulphonylamino, aminoacylamino, mono- or di-alkylaminoacylamino; with up to four R3 substituents being present in the quinoline nucleus;

or R4 is a group -(CH₂)v when cyclized onto R5 as aryl, in which t is 1,2, or 3;

R5 is branched or linear Cj.g alkyl, C3.7 cycloalkyl, C4.7 cycloalkylalkyl, optionally 5 substituted aryl, or an optionally substituted single or fused ring heterocyclic group, having aromatic character, containing from 5 to 12 ring atoms and comprising up to four hetero-atoms in the or each ring selected from S, Ο, N;

X is O, S, or N-CsN.

Examples of Ar are phenyl, optionally substituted by hydroxy, halogen, Cpg 10 alkoxy or Cj.g alkyl. Examples of halogen are chlorine and fluorine, an example of

Cj_6 alkoxy is methoxy and an example of alkyl is methyl.

Examples of Ar as a heterocyclic group are thienyl and pyridyl. Examples of Ar as a C5.7 cycloalkdienyl group is cyclohexadienyl. Examples of R are as follows:

Cpg alkyl: methyl, ethyl, n-propyl, iso-propyl, n-butyl, heptyl; phenyl ¢4.5 alkyl: benzyl;

hydroxy Ομ₆ alkyl; - CH₂OH, -CH2CH2OH, CH(Me)OH; amino alkyl: -CH₂NH₂·, di Cj_6 alkylaminoalkyl: -CH2NMe2;

Cpg alkoxylalkyl: CH2OMe;

C145 alkylcarbonyl: COMe;

alkoxycarbonyl: COOMe;

Cj_6 alkoxycarbonyl Cj_6 alkyl: CH2COOMe;

¢4,5 alkylaminocarbonyl: CONHMe;

di alkylaminocarbonyl: CONMe2, CO(l-pyrrolidinyl); halogen alkyl: trifluoromethyl;

-(CH2)p- when cyclized onto Ar:

AP/P/ 9 5 / 0 0 7 45

Example of R^ and R₂ as ¢4.5 alkyl is methyl;

Examples of R5 are cyclohexyl, phenyl optionally substituted as defined for example of Rj together with R forming a group-(CH2)q- is spirocyclopentane.

Examples of R3 and R4 are methyl, ethyl, n-propyl, n-butyl, methoxy, hydroxy, amino, chlorine, fluorine, bromine, acetyloxy, 2-(dimetylamino)ethoxy,

2-(l-phthaloyl)ethoxy, aminoethoxy, 2-(l-pyrrolidinyl)ethoxy, phthaloyl, dimethylaminopropoxy, dimethylaminoacetylamino, acetylamino, dimethylaminomethyl and phenyl.

P3O958

c c

Ar above; examples of R5 as a heterocyclic group are furyl, thienyl, pyrryl, thiazolyl, benzofuryl and pyridyl.

A preferred group of compounds of formula (I) are those in which:

Ar is phenyl, optionally substituted by alkyl or halogen; thienyl or a C5.7 cycloalkdienyl group;

R is Cj_6 alkyl, alkoxycarttonyl, Cpg alkylcarbonyl, hydroxy Cj.g alkyl;

Rj and R2 are each hydrogen or ¢4.5 alkyl;

R3 is hydrogen, hydroxy, halogen, Cj.g alkoxy, alkyl;

R4 is hydrogen, Cj.g alkyl, Cj.g alkoxy, hydroxy, amino, halogen, aminoalkoxy, mono- or di-alkylaminoalkoxy, mono- or di-alkylaminoalkyl, phthaloylalkoxy, mono- or di-alkylaminoacylamino and acylamino;

R5 is phenyl, thienyl, furyl, pyrryl and thiazolyl.

A further preferred group of compounds of formula (I) are those in which:

Ar is phenyl, 2-chlorophenyl, 2-thienyl or cyclohexadienyl;

R is methyl, ethyl, n-propyl, -COOMe, -COMe;

Rj and R2 are each hydrogen or methyl;

R3 is hydrogen, methoxy, or hydroxy;

R4 is hydrogen, methyl, ethyl, methoxy, hydroxy, amino, chlorine, bromine, dimethylaminoethoxy, 2-(l-phthaloyl)ethoxy, aminoethoxy, 2-(1pyrrolidinyl)ethoxy, dimethylaminopropoxy, dimethylaminoacetylamino, acetylamino, and dimethylaminomethyl.

R5 is phenyl, 2-thienyl, 2-furyl, 2-pyrryI, 2-thiazoIyl and 3-thienyl; and X is oxygen.

A preferred sub-group of compounds within the scope of formula (I) above is of formula (Ia):

AP/P/ 9 5 / 0 0 7 4 5

R in which;

R, R2. R3 and R4 are as defined in formula (I), and Y and Z, which may be the same or different, are each .Ar as defined in formula (T).

AP.00578

A particularly preferred group of compounds of formula (Ia) are those of formula (lb) in which the group R is oriented downward and H upward.

The compounds of formula (I) or their salts or solvates are preferably in pharmaceutically acceptable or substantially pure form. By pharmaceutically acceptable form is meant, inter alia, of a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels.

A substantially pure form will generally contain at least 50% (excluding normal pharmaceutical additives), preferably 75%, more preferably 90% and still more preferably 95% of the compound of formula (I) or its salt or solvate.

One preferred pharmaceutically acceptable form is the crystalline form, including such form in pharmaceutical composition. In the case of salts and solvates the additional ionic and solvent moieties must also be non-toxic.

Examples of pharmaceutically acceptable salts of a compound of formula (I) include the acid addition salts with the conventional pharmaceutical acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric, succinic, benzoic, ascorbic, and methanesulphonic.

Examples of pharmaceutically acceptable solvates of a compound of formula (I) include hydrates.

The compounds of formula (I) may have at least one asymmetric centre and therefore may exist in more than one stereoisomeric form. The invention extends to all such forms and to mixtures thereof, including racemates.

The invention also provides a process for the preparation of a compound of formula (I) which comprises reacting a compound of formula (ΠΙ)

R',

AP/P/ 9 5 / 0 0 7 45 (ΙΠ) in which R', R’j, R2 and Ar' are R, Rp R2 and Ar as defined for formula (I) or a group or atom convertible to R, Rj, R2 and Ar, with a compound of formula (Π)

P3O958

(Π) or an active derivative thereof, in which R'3, R'4, R5 and X' are R3, R4, R5 5 and X as defined for formula (I) or a group convertible to R3, R4, R5 and X, to form a compound of formula (Ic)

and optionally thereafter performing one or more of the following steps:

(a) where R', R'j to R5, Ar' and X' are other than R, R] to R5, Ar and X, converting any one of R’, R'j to R’5, Ar' and X' to R, Rj to R5, Ar and X to obtain a compound of formula (I), (b) where R', R ] to R’5, Ar' and X' are R, Rj to R5, Ar and X, converting any 15 one of R, Rj to R5, Ar and X to another R, Rj to R5, Ar and X, to obtain a compound of formula (I), (c) forming a salt and/or solvate of the obtained compound of formula (Ic).

Suitable active derivatives of the compounds of formula (Π) are acid halides (preferably chlorides), acid azides or acid anhydrides. Another suitable derivative is a 20 mixed anhydride formed between the acid and an alkyl chloroformate; another suitable derivative is an activated ester such as a cyanomethyl ester, thiophenyl ester, p-nitrophenyl ester, p-nitrothiophenyl ester, 2,4,6-trichlorophenyl ester, pentachlorophenyl ester, pentafluorophenyl ester, N-hydroxy-phtalimido ester, Nhydroxypiperidine ester, N-hydroxysuccinimide ester, N-hydroxy benzotriazole ester;

or the carboxy group may be activated using a carbodiimide or N,N'carbonyldiimidazole.

For example, in standard methods well known to those skilled in the art, the compounds of formula (IH) may be coupled:

(a) with an acid chloride in the presence of an inorganic or organic base in a 30 suitable aprotic solvent such as dimethylformamide (DMF) at a temperature in a

AP/P/ 9 5 / 0 0 7 4 5

AP.00578 range from -70 to 50°C (preferably in a range from -10 to 20°C), (b) with the acid in the presence of a suitable condensing agent, such as for example N,Ν’-carbonyl diimidazole (CDI) or a carbodiimide such as dicyclohexylcarbodiimide (DCC) or N-dimethylarainopropyl-N'-ethylcarbodiimide and N-hydroxybenzotriazole (HOBT) to maximise yields and avoid racemization processes (Synthesis, 453,1972) in an aprotic solvent such as a mixture of acetonitrile (MeCN) and tetrahydrofuran (THF) in a ratio from 1:9 to 7 : 3, respectively, at a temperature in a range from -70 to 50°C (preferably in a range from -10 to 25°C) (see Scheme 1),

AP/P/ 9 5 / 0 0 7 45

P3O958

P3O958 .*· \ '	3 . · · Λ :
Scheme 1
O. OH		R‘, Λ I,2 COOMe
I	R·
R'af- T if +	• 2 COOMe uN'sZ-Ar H \ DCC, HOST	r^>^YR'<R' R'4I X R1,
N R's	R\ -► 1 MeCN/THF 3:7
(II)	0-20°C (III)	(ic)
(c) with a mixed anhydride generated in situ from the acid and an alkyl (for

example isopropyl) chloroformate in a suitable aprotic solvent such as dichloromethane at a temperature in a range from -70 to 50°C (preferably in a range from -20 to 20°C).

It will be appreciated that a compound of formula (Ic) may be converted to a compound of formula (I), or one compound of formula (I) may be converted to another compound of formula (I), by interconversion of suitable substituents. Thus, certain compounds of formula (I) and (Ic) are useful intermediates in forming other compounds of the present invention.

For example R*2 may be hydrogen and converted to R2 alkyl group, for example methyl, by conventional amide alkylation procedures (Zabicky, The chemistry of amides; Interscience, London, 1970, p. 749). When X' is oxygen, it may be converted to X sulphur by standard thioamide formation reagents, such as P2S5 (Chem. Rev.,

61, 45,1961 or Angew. Chem., 78, 517,1966) or the Lawesson reagent (Tetrahedron, 41, 5061,1985). When Ar' or R'₅ is a methoxy substituted phenyl, it may be converted to another Ar' or R'5 hydroxy substituted phenyl by standard demethylation procedures via Lewis acids, such as boron tribromide (Synthesis, 249,1983) or mineral acids, such as hydrobromic or hydroiodic acid. When R is an alkoxycarbonyl group, for example methoxycarbonyl, it may be converted to another R, such as ethoxycarbonyl by transesterification with an appropriate alcohol at a temperature in a range from 20 to 120°C, carboxy by hydrolysis in acidic or basic medium, aminocarbonyl, alkylaminocarbonyl or dialkylaminocarbonyl by transamidation with ammonia, a primary amine or a secondary amine in methanol as solvent at a temperature in a range from 10 to 120°C, optionally in the presence of a catalytic amount of NaCN (J. Org. Chem., 52, 2033,1987) or by using trimethylalurainiura (MeyAl) (Tetrahedron Letters, 48, 4171,1977), hydroxymethyl by a selective metal hydride reduction, such as lithium borohydride reduction (Tetrahedron, 35, 567,

1979) or sodium borohydride reduction in THF + MeOH (Bull. Chem. Soc. Japan,

57, 1948,1984 or Synth. Commun., 12, 463,1982), alkylcarbonyl by acyl chloride formation and subsequent reaction with alkylmagnesium halides in THF as solvent at

S 7 L 0 0 / 5 6 /d/dV

P3095S

AP. Ο Ο 5 7 8 a temperature in a range from -78 to 30°C (Tetrahedron Letters, 4303,1979) or with alkylcadmium halides or dialkylcadmium in the presence of MgClg or UCl (J. Org. Chem., 47,2590,1982). Another group which R' as methoxycarbonyl can be converted into is a substituted heteroaromatic ring, such as an oxadiazole (/. Med.

Chem., 34, 2726,1991).

Scheme 2 summarizes some of the above described procedures to convert a compound of formula (Ic) or (I) in which X’ is oxygen, R‘ is COOMe, Ar and R’j to R*5 are as described for formula (I) to another compound of formula (I).

Scheme 2

The compounds of formula (I) may be converted into their pharmaceutically acceptable acid addition salts by reaction with the appropriate organic or mineral acids.

AP/P/ 95 /007 45

Solvates of the compounds of formula (I) may be formed by crystallization or recrystallization from the appropriate solvent. For example, hydrates may be formed p?fx)5S

Vr by crystallization or recrystallization from aqueous solutions, or solutions in organic solvents containing water.

Also salts or solvates of the compounds of formula (I) which are not pharmaceutically acceptable may be useful as intermediates in the production of pharmaceutically acceptable salts or solvates. Accordingly such salts or solvates also form part of this invention.

As mentioned before, the compounds of formula (I) may exist in more than one stereoisomeric form and the process of the invention may produce racemates as well as enantiomerically pure forms. To obtain pure enantiomers, appropriate enantiomerically pure primary or secondary amines of formula (Hid) or (Hie) ^R'₂ w ^R‘

H^N\^Ar·

R’i (Hie) are reacted with compounds of formula (Π), to obtain compounds of formula (Td) or (Te).

RL

R’ _H'^N\^Ar·

RL (IHd)

AP/P/ 9 5 / 0 0 7 45

Compounds of formula (Td) or (I'e) may subsequently be converted to compounds of formula (Id) or (Ie) by the methods of conversion mentioned before.

Compounds of formula (II) are known compounds or can be prepared from known compounds by known methods.

For example, the compound of formula (II), in which X' is oxygen, R'3, R'4 10

AP.00578 and R'5 are hydrogen is described in Pfitzinger, J. Prakt. Chem., 38, 582,1882 and in Pfitzinger, J. Prakt. Chem., 56, 293,1897; the compound of formula (Π), in which X' is oxygen, R'3 and R'4 are hydrogen and R'5 is 2-pyridyl is described in Risaliti, Ric. Scient., 28, 561,1958; the compound of formula (Π), in which X' is oxygen, R3 and

R’4 are hydrogen and R'5 is 0-, m- and p-chlorophenyl, σ-fluorophenyl and 3,4dichlorophenyl are described in Brown et aL, J. Am Chem. Soc., 68, 2705,1946; the compound of formula (Π). in which X' is oxygen, R'3 and R'4 are hydrogen and R’5 is p-methoxyphenyl is described in Ciusa and Luzzatto, Gazz. Chim. Ital., 44,64,1914; the compound of formula (Π), in which X' is oxygen, R‘3 and R'4 are hydrogen and

R’5 is m-trifluoromethylphenyl is described in Shargier and Lalezari, J. Chem. Eng.

Datil, 8, 276,1963; the compound of formula (Π), in which X' is oxygen, R'3 and R4 are hydrogen and R'5 isp-fluorophenyl is described in Bu Hoi et al., Rec Trav. Chim, 68, 781,1949; the compound of formula (H), in which X' is oxygen, R’3 and R’₄ are

C hydrogen and R'5 is p-methylphenyl is described in Prevost et aL, Compt. Rend.

Acad. Sci., 258,954,1964; the compound of formula (Π), in which X' is oxygen, R’3 and R'4 are hydrogen and R'5 is p-bromophenyl is described in Nicolai et aL, Eur. J. Med. Chem, 27,977,1992; the compound of formula (Π) in which X' is oxygen, R'4 and R'5 are hydrogen and R’3 is 6-methyl is described in Buchmann and Howton, J. Am Chem Soc., 68, 2718,1946; the compound of formula (Π), in which X' is oxygen, R’4 and R'5 are hydrogen and R'3 is 8-nitro is described in Buchmann et al, J. Am Chem Soc., 69,380,1947; the compound of formula (Π), in which X' is oxygen, R'4 is hydrogen, R'3 is 6-chloro, R'5 is p-chlorophenyl is described in Lutz et aL, J. Am Chem Soc., 68,1813,1946; the compound of formula (Π), in which X’ is oxygen, R'3 and R'4 are hydrogen and R'5 is 2-thiazolyl is described in Eur. Pat i 25 Appl. EP 112,776; compounds of formula (Π), in which X’ is oxygen, R3 is 8trifluoromethyl, R 4 is hydrogen and R'5 are phenyl, 0- and p-fluorophenyl, 3,4W dichlorophenyl, p-methoxyphenyl are described in Nicolai et aL, Eur. J. Med. Chem,

27,977,1992; compounds of formula (Π), in which X’ is oxygen, R'3 is 6-bromo, R'4 is hydrogen and R'5 are phenyl or p-fluorophenyl are described in Nicolai et aL, Eur.

J. Med Chem, 27, 977,1992; other compounds of formula (Π) are described in Ger. Offen. DE 3,721,222 and in Eur. Pat Appl. EP 384,313.

Compounds of formula (HI), (Hid) and (Hie) are commercially available compounds or can be prepared from known compounds by known methods (for example, compounds of formula (HI) in which R' is alkoxycarbonyl, R'j and R'₂ are hydrogen and Ar' is as defined for the compounds of formula (Ti. are described in Liebigs Ann. der Chemie, 523, 199,1936).

The activity of the compounds of formula (I) as NK3 receptor antagonists in standard tests indicates that they are of potential therapeutic utility in the treatment of

AP/P/ 9 5 / 0 0 7 45 :

P3O958 both the Primary and Secondary Disorders herein before referred to.

The discovery that NK3 receptor antagonists have potential therapeutic utility in treating the Secondary Disorders is new, and in a further aspect of the present invention there is provided the use of an NK3 receptor antagonist for the treatment of the Secondary Disorders. There is also provided the use of an NK3 receptor antagonist in the manufacture of a medicament for the treatment of any of the Secondary Disorders.

The present invention also provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for use as an active therapeutic substance.

The present invention further provides a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.

The present invention also provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of the Primary and Secondary Disorders.

Such a medicament, and a composition of this invention, may be prepared by admixture of a compound of the invention with an appropriate carrier. It may contain a diluent, binder, filler, disintegrant, flavouring agent, colouring agent, lubricant or preservative in conventional manner.

These conventional excipients may be employed for example as in the preparation of compositions of known agents for treating the conditions.

Preferably, a pharmaceutical composition of the invention is in unit dosage form and in a form adapted for use in the medical or veterinarial fields. For example, such preparations may be in a pack form accompanied by written or printed instructions for use as an agent in the treatment of the conditions.

The suitable dosage range for the compounds of the invention depends on the compound to be employed and on the condition of the patient It will also depend, inter alia, upon the relation of potency to absorbability and the frequency and route of administration.

The compound or composition of the invention may be formulated for administration by any route, and is preferably in unit dosage form or in a form that a human patient may administer to himself in a single dosage. Advantageously, the composition is suitable for oral, rectal, topical, parenteral, intravenous or intramuscular administration. Preparations may be designed to give slow release of the active ingredient.

Compositions may, for example, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.

The compositions, for example those suitable for oral administration, may 12

AP/P/ 9 5 / 0 0 7 45

AP.0 0 5 7 8 contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinyl-pyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable setting agents such as sodium lauryl sulphate.

Solid compositions may be obtained by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers.

When the composition is in the form of a tablet, powder, or lozenge, any carrier suitable for formulating solid pharmaceutical compositions may be used, examples being magnesium stearate, starch, glucose, lactose, sucrose, rice flour and chalk. Tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating. The composition may also be in the form of an ingestible capsule, for example of gelatin containing the compound, if desired with a carrier or other excipients.

Compositions for oral administration as liquids may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid compositions may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; aqueous or non-aqueous vehicles, which include edible oils, for example almond oil, fractionated coconut oil, oily esters, for example esters of glycerine, or propylene glycol, or ethyl alcohol, glycerine, water or normal saline; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.

The compounds of this invention may also be administered by a non-oral route. In accordance with routine pharmaceutical procedure, the compositions may be formulated, for example for rectal administration as a suppository. They may also be formulated for presentation in an injectable form in an aqueous or non-aqueous solution, suspension or emulsion in a pharmaceutically acceptable liquid, e.g. sterile pyrogen-free water or a parenterally acceptable oil or a mixture of liquids. The liquid may contain bacteriostatic agents, anti-oxidants or other preservatives, buffers or solutes to render the solution isotonic with the blood, thickening agents, suspending agents or other pharmaceutically acceptable additives. Such forms will be presented in unit dose form such as ampoules or disposable injection devices or in multi- dose forms such as a bottle from which the appropriate dose may be withdrawn or a solid

AP/P/ 9 5 / 0 0 7 4 5

Ρ?09?3 form or concentrate which can be used to prepare an injectable formulation.

The compounds of this invention may also be administered by inhalation, via the nasal or oral routes. Such administration can be carried out with a spray formulation comprising a compound of the invention and a suitable carrier, optionally suspended in, for example, a hydrocarbon propellant

Preferred spray formulations comprise micronised compound particles in combination with a surfactant, solvent or a dispersing agent to prevent the sedimentation of suspended particles. Preferably, the compound particle size is from about 2 to 10 microns.

A further mode of administration of the compounds of the invention comprises transdeiroal delivery utilising a skin-patch formulation. A preferred formulation comprises a compound of the invention dispersed in a pressure sensitive adhesive which adheres to the skin, thereby permitting the compound to diffuse from the adhesive through the skin for delivery to the patient For a constant rate of percutaneous absorption, pressure sensitive adhesives known in the art such as natural rubber or silicone can be used.

As mentioned above, the effective dose of compound depends on the particular compound employed, the condition of the patient and on the frequency and route of administration. A unit dose will generally contain from 20 to 1000 mg and preferably will contain from 30 to 500 mg, in particular 50, 100,150, 200, 250, 300, 350,400,450, or 500 mg. The composition may be administered once or more times a day for example 2,3 or 4 times daily, and the total daily dose for a 70 kg adult will normally be in the range 100 to 3000 mg. Alternatively the unit dose will contain from 2 to 20 mg of active ingredient and be administered in multiples, if desired, to give the preceding daily dose.

No unacceptable toxicological effects are expected with compounds of the invention when administered in accordance with the invention.

The present invention also provides a method for the treatment and/or prophylaxis of the Primary and Secondary Conditions in mammals, particularly humans, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.

The invention further provides a method for the treatment and/or prophylaxis of the Secondary Conditions in mammals, particularly humans, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective amount of an NK3 receptor antagonist

The activity of the compounds of the present invention, as NK3 ligands, is determined by their ability to inhibit the binding of the radiolabelled NK3 ligands, [125ip[M_e-Phe~]-NKB or pH]-Senktide, to guinea-pig and human NK3 receptors

AP/P/ 9 5 / 0 0 7 4 5 ζ*· (

S'

ΑΡ.00178 (Renzetti et al, 1991, Neuropeptide, 18, 104-114; Buell et al, 1992, FEBS, 299(1), 9095; Chung etal, 1994, Biochem. Biophys. Res. Common., 198(3), 967-972).

The binding assays utilized allow the determination of the concentration of the individual compound required to reduce by 50% the p25i]_[Me-Phe7]-NKB and pHJ-Senktide specific binding to NK3 receptor in equilibrium conditions (IC50). Binding assays provide for each compound tested a mean IC5g value of 2-5 separate experiments performed in duplicate or triplicate. The most potent compounds of the present invention show IC50 ^va^^ues in the range 1-1000 nM; in particular, in guineapig cortex membranes by displacement of [^HJ-Senktide, the compounds of the

Examples 22,47,48, and 85 display KjS (nM) of 5.6, 8.8,12.0 and 4.8 respectively (n=3). The NK3-antagonist activity of the compounds of the present invention is determined by their ability to inhibit senktide-induced contraction of the guinea-pig ileum (Maggi et al, 1990, Br. J. Pharmacol., 101,996-1000) and rabbit isolated iris sphincter muscle (Hall et al., 1991, Eur. J. Pharmacol., 199,9-14) and human NK3 receptors-mediated Ca⁴^ mobilization (Mochizuki et al, 1994, J. Biol. Chem., 269, 9651-9658). Guinea-pig and rabbit in-vitro functional assays provide for each compound tested a mean Kg value of 3-8 separate experiments, where Kg is the concentration of the individual compound required to produce a 2-fold rightward shift in the concentration-response curve of senktide. Human receptor functional assay allows the determination of the concentration of the individual compound required to reduce by 50% (IC50 values) the Ca*^4- mobilization induced by the agonist NKB. In this assay, the compounds of the present invention behave as antagonists.

The therapeutic potential of the compounds of the present invention in treating the conditions can be assessed using rodent disease models.

The following Descriptions illustrate the preparation of the intermediates, whereas the Examples illustrate the preparation of the compounds of the present invention. The compounds of the Examples are summarised in the Tables 1 to 6

AP/P/ 95/00745

DESCRIPTION 1

2-phenylquinoIine~4-carboxylic acid chloride

P3O95S

11.7 ml (136.3 mmol) of oxalyl chloride were dissolved in 150 ml of CH2CI2. The solution was cooled at -10°C and 20 g (80.2 mmol) of commercially available 2phenylquinoline-4-carboxylic acid were added portionwise. The reaction mixture was left overnight at room temperature and then evaporated to dryness to yield 22 g of the title compound, used without further purification.

Ci6H₁₀ClNO M.W. = 267.76

DESCRIPTION 2

7-methoxy-2-phenylquinoline-4-carboxylic add g (28.2 mmol) of 6-methoxyisatin, 4 ml (33.8 mmol) of acetophenone and 5.2 g (92.6 mmol) of potassium hydroxide were dissolved in 22.9 ml of abs. EtOH and the slurry heated at 80°C for 42 hours. After cooling of the reaction mixture, 50 ml of water were added and the solution extracted with 50 ml of Et2O. The ice-cooled aqueous phase was acidified to pH 1 with 37% HCI and the precipitate collected by filtration and washed with water.

The solid obtained was dried in-vacuo at 40°C to yield 7.0 g of the title compound. C17H13NO3

M.P. = 226-228°C M.W. = 279.30

Elemental analysis: Calcd. C,73.11; H.4.69; N.5.01;

Found C,72.07; H,4.59; N,4.90.

I.R. (KBr): 3420; 1630 cm’¹.

²⁵

DESCRIPTION 3

7-methoxy-2-phenyIquinoline-4-carboxylic add chloride

2.8 ml (32.3 mmol) of oxalyl chloride were dissolved in 60 ml of CH2CI2. The solution was cooled at -10°C and 6 g (19.0 mmol) of 7-methoxy-2-phenylquinoline4-carboxylic acid were added portionwise. The reaction mixture was left overnight at room temperature and then evaporated to dryness to yield 7 g of the title compound, used without further purification.

Ci₇H₁₂C1NO2

M.W. = 297.74

DESCRIPTION 4

7-hydroxy-2-phenylquinoline-4-carboxylic acid hydroiodide

SVZ00/56 /d/dV

P30958

AP . Ο Ο 5 7 8

1.5 g (5.4 mmol) of 7-raethoxy-2-phenylquinoline-4~carboxylic acid were added portionwise to 50 ml of 57% aqueous HI. The reaction mixture was refluxed and vigourously stirred for 5 hours; then it was evaporated in-vacuo to dryness to yield

2.1 g of the title compound.

C16HUNO3.HI M.W. = 393.17

I.R. (KBr); 3120; 1650; 1620 cm'¹.

DESCRIPTION 5

2-(2-thienyl)quinoline-4-carboxylic add g (34.0 mmol) of isatin, 4.4 ml (40.8 mmol) of 2-acetylthiophene and 6.3 g (112.2 mmol) of potassium hydroxide were dissolved in 40 ml of abs. EtOH and the slurry heated at 80°C for 16 hours. After cooling of the reaction mixture, 50 ml of water were added and the solution extracted with 50 ml of Et20. The ice-cooled aqueous phase was acidified to pH 1 with 37% HCI and the precipitate collected by filtration and washed with water.

The crude product obtained was dried in-vacuo at 40°C and triturated with EtOAc to yield 4.8 g of the title compound.

C14H9NO2S M.P. = 181-183°C M.W. = 255.29

I.R. (KBr); 1620 cm-¹.

300 MHz *H-NMR (DMSO-d₆): 5 8.60 (d, 1H); 8.45 (s, 1H); 8.10 (m, 2H); 7.78 (m,

2H); 7.68 (t, 1H); 7.22 (m, 1H).

DESCRIPTION 6

2-(2-furyI)quinoline-4-carboxylic add g (34.0 mmol) of isatin, 4 ml (40.8 mmol) of 2-acetylfuran and 6.3 g (112.2 mmol) of potassium hydroxide were dissolved in 40.9 ml of abs. EtOH and the sluny heated at 80°C for 12 hours. After cooling of the reaction mixture, 50 ml of water were added and the solution extracted with 50 ml of Et2O. The ice-cooled aqueous phase was acidified to pH 1 with 37% HCI and the precipitate collected by filtration and washed with water. The crude product obtained was dried in-vacuo at 40°C to yield

8.5 g of the title compound.

C14H9NO3

AP/P/ 9 5 / 0 0 7 4 5 i \ Γ· '''

M.W. = 239.23

DESCRIPTION Ί

2-(2-furyl)quinoline-4-carboxylic acid chloride

5.2 ml (60.4 mmol) of oxalyl chloride were dissolved in 70 ml of CH2CI2. The solution was cooled at -10°C and 8.5 g (35.5 mmol) of 2-(2-furyl)quinoline-4carboxylic acid were added portionwise. The reaction mixture was left overnight at room temperature and then evaporated to dryness to yield 9.2 g of the title compound, used without further purification.

Ci₄H₈C1NO₂ M.W. = 257.78

DESCRIPTION 8

2-(4-pyridyl)quinoline-4-carboxylic acid hydrochloride g (34.0 mmol) of isatin, 4.5 ml (40.8 mmol) of 4-acetylpyridine and 6.3 g (112.2 mmol) of potassium hydroxide were dissolved in 40 ml of abs. EtOH and the slurry heated at 80°C for 12 hours. After cooling of the reaction mixture, 50 ml of water were added and the solution extracted with 50 ml of Et2O. The ice-cooled aqueous phase was acidified to pH 1 with 37% HCI and the precipitate collected by filtration and washed with water.

The aqueous solution was evaporated in-vacuo to dryness, the residue triturated with EtOH and filtered off. Evaporation of the solvent afforded 6.0 g of the crude title compound. This product was combined with the previously obtained precipitate and recrystallized from toluene containing traces of MeOH to yield 4.5 g of the title compound.

C15H10N2O2 . HCI M.P. = 297-301°C

M.W. = 286.72

I.R. (KBr): 1705; 1635; 1610 cm-1.

300 MHz iH-NMR (DMSO-d₆): δ 8.90 (d, 2H); 8.70 (m, 2H); 8.50 (s, 2H); 8.28 (d, 1H); 7.89 (dt, 2H).

AP/P/ 9 5 / 0 0 7 45

P3O958

AP.00578

DESCRIPTION 9

2-(4-pyridyl)quinoline-4-carboxylic add chloride hydrochloride

1.3 ml (10.4 mmol) of oxalyl chloride were dissolved in 60 ml of CH2CI2. The 5 solution was cooled at -10°C and 3.0 g (14.4 mmol) of 2-(4-pyridyl)quinoline-4carboxylic acid hydrochloride were added portionwise. The reaction mixture was left hours at room temperature and then evaporated to dryness to yield 4.0 g of the title compound, used without further purification.

C15H9CIN2O HCI

M.W. = 305.22

EXAMPLE 1 (R,S)-N-(a-methyIbenzyl)-2-phenyJquinoline-4-carboxamide c

1.2 ml (9.4 mmol) of (R,S) α-methylbenzylamine and 1.6 ml (11.7 mmol) of triethylamine (TEA) were dissolved, under nitrogen athmosphere, in 50 ml of a 1:1 mixture of dry CH₂C1₂ and CH3CN.

2.0 g (7.8 mmol) of 2-phenylquinoline-4-carbonylchloride, dissolved in 50 ml of a 1:4 mixture of dry CH₂C1₂ and DMF, were added dropwise to the ice-cooled solution of the amines and the reaction was kept at 0°- 5°C for 1 hour and left at room temperature overnight

The reaction mixture was evaporated in-vacuo to dryness, the residue was dissolved in EtOAc and washed twice with a sat sol. of NaHCO3· The organic layer was separated, dried over Na₂SO4, filtered and evaporated in-vacuo to dryness.

The residual oil was crystallized from EtOAc to yield 1.1 g of the title compound as a white solid.

• C₂4H20N₂O

M.P. = 156-157°C M.W. = 352.43

Elemental analysis: Calcd. C,81.79; H^.72; N.7.95;

Found C.81.99; ΗΛ69; N/7.89.

I.R. (KBr): 3240;1645 cm'¹.

300 MHz iH-NMR (DMSO-t^): δ 9.29 (d, IH); 8.32 (d, 2H); 8.13 (d, IH); 8.13 (s,

IH); 8.06 (d, IH); 7.81 (ddd, IH); 7.68-7.52 (m, 4H); 7.47 (d, 2H); 7.39 (dd, 2H); 7.27 (dd,

1H);5.3O (dq, IH); 1.52 (d, 3H).

MS (El; source 200 °C; 70 V; 200 mA): 352 (M+.); 337; 232; 204; 77.

AP/P/' 9 5 / 0 0 7 45

P3O958

EXAMPLE 2

S-(+)-N-(a-methyIbenzyI)-2-phenylquinoline-4-carboxainide

Prepared as Ex. 1 from 1.2 ml (9.4 mmol) of S-(-)-a-methylbenzylamine, 1.6 ml (11.7 mmol) of TEA, 2.0 g (7.8 mmol) of 2-phenylquinoline-4-carbonylchloride in 100 ml of a mixture of CH2CI2, CH3CN and DMF.

The work-up of the reaction mixture was carried out in the same manner as described in Ex. 1. The residual oil was crystallized from EtOAc to yield 1.1 g of the title compound.

^ε24^Η2θΝ2θ M.P. = 161-162°C M.W. = 352.43 [a]_D ²⁰ = + 25 (C = 0.5, DMF)

I.R. (KBr): 3240; 1645 cm'¹.

300 MHz iH-NMR (DMSO-d₆): δ 9.29 (d, 1H); 8.32 (d, 2H); 8.13 (d, 1H); 8.13 (s, 1H); 8.06 (d, 1H); 7.81 (ddd, 1H); 7.68-7.52 (m, 4H); 7.47 (d, 2H); 7.39 (dd, 2H); 7.27 (dd, 1H); 5.30 (dq, 1H); 1.52 (d, 3H).

MS spactra was identical to that of the Ex. 1.

EXAMPLE 3

R-(-)-N-(a-mefliylbenzyl)-2-phenyIquinoline-4-carboxainide

Prepared as Ex. 1 from 1.2 ml (9.4 mmol) of R-(+)-a-methylbenzylamine, 1.6 ml (11.7 mmol) of TEA and 2.0 g (7.8 mmol) of 2-phenylquinoline-4-carbonylchloride in 100 ml of a mixture of CH2CI2’ CH3CN and DMF. The work-up of the reaction mixture was carried out in the same manner as described in Ex. 1. The residual oil was crystallized from EtOAc to yield 1.1 g of the title compound.

C24H20N2O

M.P.= 158-160°C M.W. = 352.43 [a]_D ²⁰ = - 25 (C = 0.5, DMF)

I.R. (KBr): 3240; 1645 cm'¹.

The iH-NMR and MS spectra were identical to those of the Ex. 1 and Ex. 2.

AP/P/ 9 5 / 0 0 7 4 5

P30958

AP.0 0 5 7 8

EXAMPLE 4 (R3)-N-[a-(methoxycar bonyl)benzyl]>2-phenylqui noli ne-4-carboxamide

2.0 g ¢8.0 mmol) of 2-phenylquinoline-4-carboxylic acid were dissolved, under nitrogen athmosphere, in 130 ml of dry THF and 100 ml of CH3CN.

2.0 g <9.9 mmol) of (D,L) methyl phenylglicinate hydrochloride and 1.5 ml (10.7 mmol) of TEA were added and the reaction mixture was cooled at 5°C.

2.5 g (12.1 mmol) of dicyclohexylcarbodiimide (DCC), dissolved in 10 ml of dry

CH2CI2, were added dropwise and the solution was allowed to reach room temperature, stirred for 5 hours and left overnight

The precipitated dicyclohexylurea was filtered off and the solution was evaporated invacuo to dryness. The residue was dissolved in CH2CI2 and then washed with H2O.

The organic layer was separated, dried over Na2S(>4 and evaporated in-vacuo to dryness to obtain 6.0 g of a crude product which was dissolved in 20 ml of CH2CI2 and left overnight Some more dicyclohexylurea precipitated and was filtered off.

The solution was evaporated in-vacuo to dryness and the residue flash chromatographed on 230-400 mesh silica gel, eluting with a mixture of hexane/ethyl acetate 3:2 containing 0.5% NH4OH. The crude solid obtained was triturated with warm 1-ΡΓ2Ο, filtered, washed and dried to yield 1.1 g of the title compound.

C25^h20N2O3 M.P. = 170-172°C M. W. = 396.45

Elemental analysis: Calcd. C,75.74; H,5.09; N.7.07;

Found C,75.88; H.5.12; N.7.06.

I.R. (nujol): 3240; 1750; 1670 cm-1.

300 MHz ^-NMR (DMSO-d^): δ 9.72 (d, 1H); 8.28 (dd, 2H); 8.20 (dd, 1H); 8.13 (dd, 1H); 8.11 (s, 1H); 7.83 (ddd, 1H); 7.66 (ddd, 1H); 7.60-7.50 (m, 5H); 7.47-7.37 (m,

3H); 5.78 (d, 1H); 3.72 (s, 3H).

MS (El; source 200 °C; 70 V; 200 mA): 396 (M+.); 337; 232; 204.

AP/P/ 9 5 / 0 0 7 45

EXAMPLE 5 (+)-(S)-N-[a-(methoxycarbonyl)benzyl]-2-phenyIquinoline-4-carboxamide

V , ·'·

2.0 g (8.0 mmol) of 2-phenylquinoline-4-carboxylic acid were dissolved, under nitrogen athmosphere, in 70 ml of dry THF and 30 ml of CH3CN.

1.7 g (8.4 mmol) of (L) methyl phenylglicinate hydrochloride, 1.1 ml (9.9 mmol) of N-methylmorpholine and 2.1 g (15.5 mmol) of N-hydroxybenzotriazole (HOBT) were added and the reaction mixture was cooled at 0°C.

1.85 g (9.0 mmol) of DCC, dissolved in 10 ml of CH2CI2, were added dropwise and the solution was kept at O’- 5’C for 1 hour and then at room temperature for 2 hours. The precipitated dicyclohexylurea was filtered off and the solution evaporated invacuo to dryness. The residue was dissolved in CH2CI2 and washed with H2O, saL sol. NaHCO3,5% citric acid, sat. sol. NaHCC>3 and sat. sol. NaCl.

The organic layer was separated, dried over Na2SC>4 and evaporated in-vacuo to dryness; the residue was dissolved in 20 ml of CH2CI2 and left overnight Some more dicyclohexylurea precipitated and was filtered off.

The solution was evaporated in-vacuo to dryness to obtain 2.6 g of a crude product which was triturated with petroleum ether, filtered, washed with /'-ΡΓ2Ο and then recrystallized from 70 ml of i'-PrOH to yield 1.7 g of the title compound.

^c25^H20N2°3 M.P. = 180-181° C M.W. = 396.45

I.R. (nujol); 3300; 1750; 1640 cm¹.

[a]_D ²⁰ = +42.0 (C = 0.5, MeOH).

The ^H-NMR and MS spectra were identical to those of Ex. 4.

EXAMPLE 6 (-)-(R)-N-[a-(methoxycarbonyl)benzyl] -2-phenylquinoline-4-carboxamide

Prepared as Ex. 5 from 2.0 g (8.0 mmol) of 2-phenylquinoline-4-carboxylic acid, 1.7 g (8.4 mmol) of (D) methyl phenylglicinate hydrochloride, 1.1 ml (9.9 mmol) of Nmethylmorpholine, 2.1 g (15.5 mmol) of HOBT and 1.85g (9.0 mmol) of DCC in 70 ml of dry THF and 30 ml of CH3CN.

The work-up of the reaction mixture was carried out in the same manner as described in Ex. 5. The crude product obtained (3.5 g ) was triturated twice with warm j-P^O, filtered, washed and then recrystallized from 80 ml of i-PrOH to yield 2.3 g of the title compound.

C25H20N2O3

M.P. = 180-181°C M.W. = 396.45

I.R. (nujol): 3300; 1750; 1640 cm-¹.

AP/P/ 9 5 / 0 0 7 45

- -.....AP . Ο Ο 5 7 8 [a]_D ²⁰ = -42.0 (C = 0.5, MeOH).

The ^H-NMR and MS spectra were identical to those of Exs. 4 and 5.

EXAMPLE 7 (R,S)-N-[a-(m€thoxycarbonyl)benzyl] -7-methoxy-2-phenylquinoline-4carboxamide

1.0 g (5.0 mmol) of (D.L) methyl phenylglicinate hydrochloride were dissolved, under nitrogen athmosphere, in 30 ml of dry DMF.

2.5 g (18.1 mmol) of anhydrous potassium carbonate were added and the solution cooled at 0°C.

0.7 g (2.3 mmol) of the compound of Description 3, dissolved in 25 ml of dry DMF, were added dropwise and the solution was kept at 0°- 5°C for 1 hour and at room temperature overnight

The reaction mixture was evaporated in-vacuo to dryness and the residue was dissolved in EtOAc and washed twice with H2O. The organic layer was separated, dried over Na2SO4> filtered and evaporated in-vacuo to dryness.

The residual oil was flash chromatographed on 230-400 mesh silica gel, eluting with a mixture of hexane/ethyl acetate 3:2 containing 0.5% NH4OH to afford 0.1 g of the crude product which was triturated with i-P^O to yield 0.08 g of the title compound.

^26Η22^Ν2θ4 M.P.«187-190°C M.W.= 426.48

I.R. (KBr): 3220; 1750; 1660; 1620 cm'¹.

300 MHz iH-NMR (CDCI3): δ : 8.13-8.08 (m, 3H); 7.80 (s, IH); 7.55-7.38 (m, 9H);

7.21 (dd, IH); 7.02 (d broad, H); 5.88 (d, IH); 3.97 (s,3H); 3.80 (s, 3H).

MS (El; source 200 °C; 70 V; 200 mA); 426 (M+.); 367 ; 262 ; 234; 191 ;77.

EXAMPLE 8 (R,S)-N-[a-(methoxycarbonyI)benzyl]-7-hydroxy-2-phenylquinoUne-4carboxamide

Prepared as Ex. 5 from 2.1 g (5.3 mmol) of the compound of Description 4, 1.08 g (5.3 mmol) of (D,L) methyl phenylglicinate hydrochloride, 1.5 ml (10.7 mmol) of

TEA, 1.7 g (12.5 mmol) of HOBT and 1.2 g (5.8 mmol) of DCC in 70 ml of dry THF and 30 ml of CH3CN.

The work-up of the reaction mixture was carried out in the same manner as described

AP/P/ 9 5 / 0 0 7 45

P30958 in Ex. 5. The crude product obtained was triturated with i-P^O and then recrystallized twice from i-PrOH to yield 0.06 g of the title compound.

^c25^H20^N2°4 M.P. = 256-257°C

M.W. =412.45

I.R. (KBr): 3270; 1750; 1650; 1620 cm’¹.

300 MHz iH-NMR (DMSO-d^): δ 10.30 (s broad, IH); 9.64 (d, IH); 8.22 (d, 2H);

8.04 (d, IH); 7.85 (s, IH); 7.60-7.34 (ra, 9H); 7.21 (dd, IH); 5.74 (d, IH); 3.71 (s, 3H).

MS (El; source 200 °C; 70 V; 200 mA): 412 (M+.); 353; 248; 220; 77.

EXAMPLE 9 (R3)-N-[a-(carboxy)benzyl]-7-methoxy-2-phenylquinoline-4-carboxamide hydrochloride

0.18 g (0.4 mmol) of the product of Ex. 7 were dissolved in 10 ml of 10% HCI and 5 ml of dioxane. The reaction mixture was refluxed and stirred for 3 hours, then evaporated in-vacuo to dryness.

The crude product was triturated with warm EtOAc (containing a few drops of EtOH) 20 to yield 0.16 g of the title compound.

C25H20N2O4.HCI M.P. = 228-230°C M.W. =448.91

I.R. (KBr); 3180; 1735; 1655; 1630 cm-1.

_? . 25 300 MHz iH-NMR (DMSO-d^): δ 9.6 (d, IH); 8.26 (dd, 2H); 8.14 (d, IH); 7.98 (s,

IH); 7.63-7.52 (m, 6H); 7.46-7.36 (m, 3H); 7.33 @ (dd, IH); 5.66 (d, IH); 3.98 (s, 3H).

MS (El; source 200 °C; 70 V; 200 mA): 412 (M+.); 368 ; 262; 234; 191; 77.

EXAMPLE 10 (R3)-N-[a-(methylaminocarbonyl)benzy]]-2-phenylquinoline-4-carboxamide

0.45 g (1.1 mmol) of the product of Ex. 4 were dissolved in 40 ml of 33% MeNH2/EtOH; a catalitic amount of NaCN was added and the reaction mixture was heated at 70°C for 1 hour in a parr apparatus. The internal pressure rised to 40 psi.

The solution was evaporated in-vacuo to dryness and the residue was triturated with water, filtered, dried and recrystallized from a mixture of z'-PrOH (50 ml) and EtOH (30 ml) to yield 0.2 g of the title compound.

AP/P/ 9 5 / 0 0 7 45 η At

AP.00578

C25H21N3O2 M.P. = 261-263°C M.W. = 395.47 _;

Elemental analysis: Calcd. C,75.93; H,5.35; N,10.63;

Found C,75.65; H,5.34; N, 10.55.

I.R. (KBr): 3300; 3270; 1660; 1635 cm-¹.

300 MHz JH-NMR (DMSO-t^): 5 9.48 (d, 1H); 8.33-8.25 (m, 3H); 8.18-8.10 (m, 3H); 7.80 (ddd, 1H); 7.68-7.50 (m, 6H); 7.407.28 (m, 3H); 5.75 (d, 1H); 2.63 (d,3H).

MS (El; source 200 °C; 70 V; 200 mA): 395 (M+.); 337; 232; 204; 77.

EXAMPLE 11 (R3>*N-[a-(inethoxycarbonyl)benzyl]-2-(2-thienyl)quinoline-4-carboxainide

Prepared as Ex. 5 from 2.0 g (7.3 mmol) of 2-(2-thienyl)quinoline-4-carboxylic acid,

1.7 g (8.4 mmol) of (D,L) methyl phenylglicinate hydrochloride, 1.1 ml (10 mmol) of N-methylmorpholine, 2.1 g (15.5 mmol) of HOBT and 1.85 g (9.0 mmol) of DCC in 70 ml of dry THF, 30 ml of CH3CN and 10 ml of CH₂C1₂.

The work-up of the reaction mixture was carried out in the same manner as described 20 in Ex. 5. The crude product obtained was crystallized from EtOAc and then recrystallized from abs. EtOH to yield 0.9 g of the title compound.

C23H18N2O3SL M.P. = 178-180°C M.W. = 402.47

Elemental analysis: Calcd. C,68.64; H.4.51; N.6.96;.

Found C,67.50; H.4.99; N,7.43.

I.R. (KBr): 3300; 1745; 1645 cm'¹.

300 MHz ^-NMR (DMSO-d₆): 5 9.70 (d, 1H); 8.12 (d, 1H); 8.08 (s, 1H); 8.04 (d, 1H); 8.02 (d, 1H); 7.19 (t, 1H); 7.76 (d, 1H);

7.62 (t, 1H); 7.53 (d, 2H); 7.46-7.37 (m, 3H); 7.3 (dd, 1H); 5.68 (d, 1H); 3.68 (s, 3H).

MS (El; source 200 °C; 70 V; 200 mA): 402 (M+.); 343; 238; 210; 77.

EXAMPLE 12 , (R,S)-N-[a-(methoxycarbonyI)benzyl]-2-(2-furyI)quinoline-4-carboxamide

Prepared as Ex. 1 from 7.2 g (35.5 mmol) of (D,L) methyl phenylglicinate hydrochloride, 12.4 ml (88.8 mmol) of TEA and 9.1 g (35.5 mmol) of crude 2-(2AP/P/ 9 5 / 0 0 7 4 5 furyl)quinoline-4-carbonylchloride in 350 ml of a mixture of CH2CI2, CH3CN and DMF. The work-up of the reaction mixture was carried out in the same manner as described in Ex. 1. The crude product obtained was triturated with MeOH to yield 3.3 g of the title compound.

^{5 C}23^H18^N2°4

M.P. = 178-180°C M.W. = 386.405

Elemental analysis: Calcd. C,71.49; H.4.70; N.7.25;

Found C,71.67; H.4.74; N,7.17.

I.R. (KBr): 3300; 1750; 1650 cm*¹.

300 MHz iH-NMR (DMSO-d₆): 5 9.72 (d, 1H); 8,12 (d, 1H); 8.06 (d, 1H); 7.96 (dd, 1H); 7.92 (s, 1H); 7.80 (ddd, 1H); 7.62 (ddd, 1H); 7.52 (dd, 2H); 7.45-7.35 (m, 4H); 6.73 (dd, 1H); 5.77 (d, 1H); 3.74 (s, 3H).

MS (El; source 200 °C; 70 V; 200 mA): 386 (M+.); 327; 222; 194; 77.

EXAMPLE 13 (R3)-N-[a-(methoxycarbonyl)benzyI]-2-(4-pyridyl)quinoline-4-carboxamide

Prepared as Ex. 1 from 3.4 g (16.7 mmol) of (D,L) methyl phenylglicinate hydrochloride, 3.9 ml (27.8 mmol) of TEA and 3.0 g (11.1 mmol) of 2-(4pyridyl)quinoline-4-carbonylchloride in 100 ml of a mixture of CH2CI2» CH3CN and DMF. The work-up of the reaction mixture was carried out in the same manner as described in Ex. 1. The crude product obtained was recrystallized three times from

EtOAc to yield 1.9 g of the title compound.

C24H19N3O3 M.P. = 172-174°C M.W. = 397.43

Elemental analysis: Calcd. C,72.53; H,4.82; N, 10.57;

Found C,71.87; H,4.87; N,10.44.

I.R. (KBr): 3240; 1750; 1670 cm*¹.

300 MHz iH-NMR (DMSO-d₆): 5 9.74 (d, 1H); 8.79 (dd, 2H); 8.27-8.17 (m, 5H);

7.89 (ddd, 1H); 7.74 (ddd, 1H); 7.54 (dd, 2H); 7.47-7.38 (m, 3H); 5.8 (d, 1H); 3.75 (s, 3H).

MS (El; source 200 °C: 70 V; 200 mA): 397 (M+.); 338; 233; 205; 77.

EXAMPLE 14 (R,S)-N-[a-(methoxycarbonyl)-2-thienylmethyl]-2-phenylquinoline-4AP/P/ 9 5 / 0 0 7 45

P30958

AP.00578 carboxamide

Prepared as Ex. 1 from 1.94 g (9.4 mmol) of (D,L) methyl thienylglicinate hydrochloride, 2.7 ml (19.5 mmol) of TEA and 2.0 g (7.8 mmol) of 25 phenylquinoline-4-carbonylchloride in 100 ml of a mixture of CH2CI2’ CH3CN and DMF. The work-up of the reaction mixture was carried out in the same manner as described in Ex. 1. The crude product obtained was recrystallized three times from EtOAc to yield 0.66 g of the title compound.

C23H18N2O3S 10 M.P. - 144-145°C

M.W. = 402.47

Elemental analysis: Calcd. C,68.64; H,4.51; N,6.96;

Found C.68.81; H.4.46; N,6.96.

I.R. (KBr): 3295; 1745; 1640 cm-¹.

300 MHz to-NMR (CDCI3): δ 8.25 (dd, IH); 8.22 (dd, IH); 8.17 (dd, 2H); 7.95 (s,

IH); 7.78 (ddd, IH); 7.60 (ddd, IH); 7.56-7.45 (m, 3H); 7.35 (dd,lH); 7.20 (d, IH); 7.05 (dd, IH); 7.05 (s broad, IH); 6.22 (d, IH); 3.9 (s, 3H).

MS (El; source 200 °C; 70 V; 200 mA): 402 (M+.); 343; 232; 204.

EXAMPLE 15 (R3)-N-[a-(methoxycarbonylmethyl)benzyI]-2-phenyIquinoline-4-carboxaniide

Prepared as Ex. 5 from 1.39 g (5.60 mmol) of 2-phenylquinoline-4-carboxylic acid,

1.2 g (5.60 mmol) of (R,S) methyl 3-amino-3-phenylpropionate hydrochloride, 0.78 ml (5.60 mmol) of TEA, 1.51 g (11.2 mmol) of HOBT and 2.31 g (11.2 mmol) of DCC in 10 ml of dry THF, 4 ml of CH3CN and 7 ml of CH2CI2. The work-up of the reaction mixture was carried out in the same manner as described in Ex. 5. The crude product obtained was dissolved in CH2CI2 and left at 0°C overnight Some more dicyciohexylurea precipitated and was filtered off.

The solution was evaporated in-vacuo to dryness to obtain 1.4 g of a crude product which was triturated with a mixture of i-Pr2O/acetone 99:1 to yield 1.2 g of the title compound as a white solid.

^C26^H22^N2°3

M.P. = 156-158°C M.W. = 410.47

Elemental analysis: Calcd. C,76.07; H,5.40; N,6.82;

Found C,75.77; H,5.38; N,6.94.

AP/P/ 9 5 / 0 0 7 4 5

P3Q95S if

I.R. (KBr): 3295; 1755; 1645; 1590; 1530 cm-¹.

300 MHz iH-NMR (DMSO-d₆): δ 9.40 (d, IH); 8.29 (dd, 2H); 8.14 (d. IH); 8.07 (d, IH); 8.04 (s, IH); 7.83 (ddd, IH); 7.66-7.52 (ra, 4H); 7.50 (d, 2H); 7.40 (dd, 2H); 7.31 (ddd, IH);

5.60 (dt, IH); 3.65 (s, 3H); 3.04-2.89 (m, 2H).

MS (El; source 200 °C; 70 V; 200 mA): 410 (M+.); 337; 233; 205.

AP/P/ 9 5 / 0 0 7 45

TABLE 1

AP.00578

U2

Q .—I e

4J >

AP/P/ q 5 / 0 0 7 4 5

I he compounds of the Examples 16-49 of general formula (I) (grouped in the following Table 2) were synthesized starting from the appropriate acyl chlorides of (11) and amines of formula (III) shown in the table and following the synthetic procedure described in Example 1. Acyl chlorides were synthesized starting from the corresponding acid of formula (II) and following Description 1. Reaction yields are calculated on the purified, but unrecrystallized material. Analytical and spectroscopic data of the compounds of the Examples 16-49 are grouped in Table 5.

U /Q/u V

ι.

P.W58

ΑΡ . Ο Ο 5 7 8

X e5 « ® S » -Γ II w >»·✓				-36.0	Ch >ri cn +
m.p. (°C) (recryst solv.)	® Ϊ ί § Se	0© /-s oo X o T Q i? oe !±	sis zip ZJ « CU CC js Γ3	m o >n o τ ε1 cn £ in O	Ό O in o T £» «η £ <n a
yield (%)	o cc	cc Tf	tT CN	00 in	00 t-~
£ •	00 <n ri cn v	CS in <5 cc	cn so *n	c* ό 00 cc	O' Tj- © 00 cn
Molecular formula	<S z © cn X σ\ cn U	cn o cn Z < CN X oo cn U	O CN z < cn X cn U	o CN z < CN X O CN U	o CN z -<· CN X so ύ*
Stereo chemistry	<Z) o£	(λ o4	(λ οι		oi
	Q“= γ ? & xz >=< ° n		Pi« 33 y=x ° n	X 0. — Υω· £ I 2 oxz <K> y //	r“jυ4 •Έ
(III)	p. z- X	Pl z M I	R. z M X	Q. J.IUI z X*	I
Acyl chloride of (11)	□ tO F C Q-	λθ	t s f //	Φ 5 x \ \\ //	_ if v //
X ΰ	S'	cn	CN	CN CN	cc CS

LT »4

Γ

C

Ο

Ι’3<1958 t -

X ® 0 cm « a s ΰ r “ II «
>
rj ®	v> TJ·	0 ς?	T?	2 0	Ον TJ1
o “	<n c	198-20 (tolueni	C ** 4) • *5 so 2	®5 c	— β
m.p. ( ecryst	124- (tolue	193- (tolui	1 s Γ- —
wM **
La
T3 2	IT) M->	σ>	<c r-	4	CM
>>
	OC	t—		vo	CC
£		IC		CC
	vd	<4		IC	00 cc
s				TT
ecular mula	CM z cm CM	</ CM z Ό CM	cn CM Z tb 0	0 CM	CM «—> CM z 0 CM
*S o S 12	se vO CM u	X CC U	X Ml CM U	CM X v> CM U	X Tt CM u
eo Istry
CA	CA	CA	<z>	CA
S £	oi	Oi	Oi	oi	Oi
» «
U
	£		Φ 2	0 δ
	o	UJ X	Q		('VS
	Ύ o-Q	Τέ £	x: 0 Ύ -Q	ί
>·✓	Η ?t{ WX /	cK?	x z Z f—(	:¾	IZ ZG\
	0 /Λ	V V	° / \		0 n
				G	G
				δ δ
(III)	0.8 /-0		COOMe		r° OH
			z~	/-ω
	z	z	z		z
				X
ide	i /=\	j= £ CL Q-		x: Ο.	X a.
5 C	V-G2	0	δ /~f	ο ζ=\	<·> /=λ
* “	^Y-?2	Γ?
			ofr—(\ x.Z
-, ®
0' <	\\ //		\\ //
X		IC	vC	r*	X
£	CJ	CM	CM	CM	CM

t, V L 0 0 / * ⁰ /a/uv

AP . 0 0 578

P30958

[«Id20 (c=l, MeOH)
m.p. (°C) (recryst solv.)	141-143 (toluene)	— ω ©- oo c O — « 04 1 S Ab © -= £ OO ® ·-	156-158 (toluene/ hexane)	180-183 (toluene)	179-181 (toluene)
Ό *S gS	©	©	vn	oc	00
►>
£	r-~	00	o Tf	© c>	00 -T
	'd Ό ec	o	00 en	cn ’’fr	Tt
Molecular formula	o CS z es es a «η es U	cn c CS Z rs es X \O CS U	CS z ’t CS X \o es U	cn (S Z u X «η es U	cn o es z CS es X so CS U
Λ 0
Stereo chemist	C/3 Qi	oc Qi	c/3 Οί	iz? Qi	5? Qi
(I)	Q. , j—ω o. yQ	«rg	% \\ //	Rj , xz /=X ° n	Qj , )-O e. 1Kz
				ΰ
WM a	R.	3-1	7. 2	Al	qi
	Z CM I	M X	X	w X	<m X
irlde )	£ CL	® £ 2 Q-	• £ 2 a. ο	X CL	s.
clilt f (II	<Κί
Acyl o	/)	/)	\> /)	\< // o	Y // έ
Ex.	o CS	cn	cn	<s en	cn cn

cn cn tr

AP/P/ Q ί /(1(174

< f'·

1*30958

w> © 0 CN « o s d _u “ II o
m.p. (°C) (recrysL solv.)	144-145 (toluene) 1	197-199 (toluene)	156-157 (toluene/ hexane )	149-150 (toluene)	O\ \ 2 0 0 T CM £? 2 S -¾
yield (%)	cn	Tt	CN ΙΛ	© «Λ	eo uo
M.W.	r- cn OO eo	© © © cn •n·	o io Tt CN	o\ Tt o OO eo	CN WO Tt eo
Molecular formula	CN c CN z CN CN SC V> CN u	C~. C CN z u © x m CN U	cn CN z CN X r~ CN U	CN z CN X © CN u	z © CN X r- CN U
Stereo chemistry	OS	co ai	co d Sv'	co oi	5? oi
	φ,	Ql , Λ-ο S. TZ <k> \\ // ϋ	i Q Xc Λ xz Λ—' ° Ο	xz Z—' <q>	J^z s. 12 ° n
(ΠΙ)	R5 z M X	COOMe	Rs z *· X	R« z c« X	R. X
Acyl chloride of (II)	c. 0. \\ /)	£ 0. X< \\ // δ	~ £ uj a.	£ D_ \\ //	~ £ UJ CL Mr V—7
ω	*3· eO	IO, ro	eo	r- c*\	00 <T.

cn

AP . Ο Ο 5 7 8

P30958

X d			-49.8 (c=0.2)	-60.5
Ο £	2 •k II
υ	► I	© c	ΰο ϊ «	cn Ο O	2 ο x o© e -E	Z o d V
	U	d «	τ a «	<? d d	T 5 O
ο. έ	&	' s ο 15 d ο	σ\ Λ κ -t 3· ·=	2 ω a- <N	-i K Ux g JS .¾	o ω © 5 d £
S υ	ίδ	Ό		d	O\ ΓΊ	$
►>
		ΟΟ		©	©	oo
£		»Α	ν>	cn	'f	Tt
		—	οο	CO	Os	SO
S		Wi	§	IT)	’t	Tt
Molecular	β Έ g £	cn —Κ — cn Ζ •ο d X cn cn U	Ο d Ζ οο d X οο d υ	o d z ε1 CQ d d X sc d U	O d Z fc· CQ cn d X Ό d u	o d z d d %
tereo
ε	οο oi	<Ζ5 t£	/-*v co	z-s CZ3	co C4
ce	« JS	</	SmZ
	ο
		%»,	,	£ y4 w	<£ *» a. ui / \ J’V/
z-s Μ		Ο ν/ °η/	I ν ζ χζ {	7-χ	ο*χ
		XZ / \	° / \	/ \	v_y
			ν_7	y //	/	r1
		έ		&	ώ	i
Z“\ ε		R.	Α-.	Q. JO UJ	q.	Rj
				z	z	z
		X	X	X	X	X
4>		ιί^ι		co	z=\	JZ 0.
ο Έ β 5 Τ> ν <	«Μ Ο	τ>% 4~ζ. 0- °°τ£$	£L £ C 0. ^~S	Ok, Cl ί^τΛτ^	® V V “ 2 Jr Hz	x< w // 2
		γ //			ffl	s
				co
X			*>		d	cn
ω		e**.	Tt		TT	Tt

ΑΡ/Ρ/ 9 / η η 7 ί τ

Ι'3Ο95Χ

R* w S 2 £ ~ II				-45	(c=0.5)
X“S
rj ό o « «J _· «	0-241 tOAc)	4-196 lOAc)	0-181 luene)	2-134	O u CN ω
ε «	•*t ΓΤ] CN ©·	2 (£	00 o	CC	s
u
T3 J· »Λ	vc	r*	m	oc
a»	l©	rt		m
>>
	Γ-	CC	, .	o\
£	M·	ic	rt	rt
	\d	oc	\C	id
s	CC	CM	o	OS
		rt	CC
				CM
u α a	o CM	o CN	CM z	o CM
ecul ntul	z © CN	z •’fr CN	cn U. r-	z ’t CN
Mol for	X CN u	X © Cl U	X rt cs U	X lO CN U
>>
o b
tere mis	CZ3 at	CO αέ	CZ5 0£	CA •*w-*
*> 5			****
CJ
	• ΓΗ
	-5 Λο- JJ	\ / -C	\-/
	\ 8		y& £	'“W	£
'w'	XZ /=\	12 /=(	XZ >
	λ—Z z	Ky	h*	-Tv	J2
				O >
	° <5	G	G		_y
	G |	G G	G .	G
MM	>8		\ u.	\ -
		>-O	/»1 Ul
	z	z	z	z
	N X	z	I	x
	1 1			•
B	-Z		.c a.	Σ s.
ori 1)	o /			_ o a
Ξ			r^GZ	/2
	\ / — \
0M S	\_Λ z	/ \	/ \	O ) y.
	c> /—	\\ //	V_y	\\_ 7
·<
χ	rt	w~, rt	c	r-
r-^4 M	rt	rt	rt

AP/P/9 ^/0074^

PJ0958

AP. Ο Ο 5 7 8

® o Π V ® s « u.	-42 (c=0.5) 1
►
χ·\ * « 8 «I	120	ane)		oc r-	c 2
m.p. ecrys	00	X 0 JS		(-. r—	9 2 SwZ
Ό /-.
3		53		0
►»
		04		t
£		in		Os
		Tt		O’
s		Os		O
	co		TT
		0		C 04
a as		fS Z sO		z
S 3			u
•s ί		<N £		cm
				£
2 *		CM U		m rM O
tereo mist
	y*s		50 Bi
Si che
			0
	w	LU		,)
	v	* -C		-<
_	r	UJ 0.		>-ffi	C
	XZ
	X		XZ Z=A
	0	K		O-	<
				c	?
			O
	/7~\
			ft
	N=Z		\-/
	> z	hi ui	ye
	I			z
				I
oride I)	c 0 5	έ	0	£. a.
Λ ~	ΛΆ'	A2		-0=
W b. — 0	0 /		0
>»	V	L·/		V V
<
X		oc	O'.
ϋ			TT

Γγο

7/00/9 o/ci/dV

I he compounds of the Examples 50-88 of general formula (I) (grouped in the following Table 3) were synthesized starting from the appropriate reagents (II) and (III) shown in the table and following the synthetic procedure described in Example 5. Reaction yields are calculated on the purified, but unrecrystallized material. Analytical and spectroscopic data of the compounds of the Examples 50-88 are grouped in Table 5.

X © © £ s β « II
>
M
fj β o w	© a <n a	r- a	2 %
	τ o	τ o
• «ft	00 £ CM “j	69 iPr	o
ε u			04 ω
-a
		oo
		00
►»
	oc	Γ'	O\
£		V
		ci	ci
3	»—«	©	<N
MC
u	ec o	co r»i o	ec ©
β «	CM		<s
9 9	2	z	2
	CM CM	oc	CM CM
δ δ	a	a	a
	Ό	ec	c* CM
	u	υ	u
e f
	CO	co	CO
« ε	Q&	os*	os
55 «
w
	Ql Tvs t	COOMe	9
£5-	5-Z /=·(	XZ —	XZ / —'
			K_/
		O f—\
	Q	\\ /)	G
a	χ	91	9-?
	Z	z	z
	Φ S	X	x~
		w
	x:
	X Q-	v V	/~λΛ //
	n /	X T·7	X \ /—'
	0 /	O __(
	O-G ,z	O / “
		°	°G2
	\\ /)	/\
		\\ //	w
		M	ΓΊ
a	LT.	IC	tr,

AP/P/ 9 3^s / 0 0 7 4

AP . Ο Ο 5 7 8

P30958

X β 0 <Μ « ο 5 r—r A 8 U“ “ II ο 'w'
m.p. (°C) (recrysL solv.)	oo X il	3 ® <7 O © .¾ CM s»z	00 X cr ? 00 .¾	·§ 33 ο R 2 ? £ & £ W·*
yield (%)		© vn	v> Os	Γ- Ι’-
£	CN Ή	CH	ν’) 't	CN Vi ·*τ
	00 cn	© 't	cr	© CH
Molecular formula	σι o m Z Os X co CN U	tO cr o cr z r- X CN cn U	O CN z © CN X V) CN (J	ο CN Ζ Ό CN X CN υ
ereo nlstry
		CO	to
w jl Q	00	B5	Obi V-/
	RU XZ 1	Qie >-O Jp-» XZ y—ς <Κ>	%	3-<· yc^
	° o	\\ y	° <5
ί (ra)	Rj z At X	Η,ΝγΟ COOMe	M a	R-. ζ ΓΜ X
	/vs _ v-2		§ £	X_£
(II)	8 /=< 1 °~v*z	X / o _/ °Gz	δ_Μ2	° λ-ΑΖ
	v_y	υ //	Y ff	γ //
Ex.	CH <C	ir>	V) V)	© UH

ο* (Si

ΛΡ/Ρ/ ο / π η 7 ζ, '·* »- + *

X S 2 fi s II w
Q $ o w	? X	OC Λ CN Λ	So x	So x
U	T o	Ύ £>	-r o	T 0
• «- £?	£ £	CN .¾	80 iPr	CN ±oc 5;
C t * 4i	S—✓		—
u
Ό >->»
	CC		Ov	cn
v Ss	00	Ov	C~	VO
*►»
	oc	©	00	OC
	Tt	VO	tT
	©	<3	©	VC
		Γ*Ί		CM
«	'T		Tt	Tf
	C*>		<ΤΊ
u os ea	o CN	o CN	o CN	c CN
ecu! mul	z CN CN	z CN cn	z CN CN	z CN CN
Mol for	X vo CN	X © cn	X v© CN	X VO CN
	U	vJ	u	u
A U 9 **			Z**N
<V 4ft	Vi	Vi	Vi	CZ3
«i	a£	0£	Di	Di
» «				**«✓
u
	w‘ xz /=\	% XZ /xr\	Ttp	HyO COOMe X^l
	<Kz	° rS	οΚίΖ 3	crfr
	V?			\( /)
z-“\ M	Τ’ COOMe	r© nHepty, I	TJ	T^
	zn	z CM	z	z^
	X	X	X	X
	©			i
				o
	<=-(	X &	ν y
	\\ //	o _/	x >—(	\\ //
(ID	o		8 _r^ j O-G ,2 s	X J—/
	°-Qz	v y	/\
	/ A		v_y	j \
	v_y			v_y
X	r-	oc	Ov
ω	l/T	iz^	1/Ί	sC

ί L U U / >,ϊ ό /d/d V

AP.00578

P3(W58

as * 2 -9 5 £ ~ {!>
m.p. (°C) (recryst solv.)	164-165 (iPrOH)	226-227 (iPrOH)	1 186-187 (iPrOH)	173-174 (iPrOH)
yield (%)	cm 00	©	© r—	«η r-~
M.W.	V} cm O' cr	«η cm’ •V	© Ί- Ο 'T T	Γ- Tt © © cr
Molecular formula	o CM z M- CM X CM	'ί- Ο CM z © CM X «Λ CM u	V> O CM z 04 X © CM u	O CM Z CM CM X ur CM tj
Stereo chemistry 1	1 «	co oi	cd	1 »
M	° o	xz ° o	w- XZ /=< ° o	crw
w	X	Rj z et Z	H,NyO COOMe	z*3 et X
	X £ o __( \ /)	X 0 x y--' Ο Ζ=λ v_y	<\ J-o X f' °“Cz \\_y	X £ 8-0z \\ //
X	ό	CM ©	cr ©	Ό

AP/P/ 9 5 / 0 0 7 4 5

P3O958

X ® 2 Ο S β ~ II υ				-6.9 (c=0.5)
~ ί υ © ρ . ·	oi G © X	ο o ΟΊ <\j	Vft X so X »—· <*s	2 § 6
m.p. 1 (recryst	S? © a Ό *“	£/ <s ft © 35 CS	1 Sft 3 A so ©*	1 cS A A eft 35 .¾
yield (%)	© Os	©	OS Wft	Os 3
£	Os 3 © OO eft	(S 1/S oo «	3 eft Oft SO 3	Vft 3 r-’ © eft
Molecular formula	O CS z 3 CS X SO CS u	c**i o eft z os X eft CS U	eft /-* su CS z CS 0 00 X V) CS U	O eft Z« CS X 3 CS CJ
Stere< chemist	S S	S	05	S
/**s.	>.x£f rT Y^PI,	oi s- \=J δ ^zx V° /=7 xz /=\ o^Q	ΟγΙΙγΟ sJb. COOMe N Ύχ ci	Q<o >'θ XZ Z=\
	\s //	\s /)	V //	V—J
(III)	i R. z e* x	Rj z W X	HaNyO COOMe	O°v4 >-/ O Za I
			o o
	c χ 0-	ZI I		\\ // x f—'
·*—'	«-o v_y	8~C2 v_z	O _/ °~C/ v_y	O / 8~C2 \s /)
• Ex.	U~, c	\C	Γ- Ό	x

Ό

C

C3 >

υ

ο.

ίΛ σ\ «

ο

5»

Ua ο

ω ιη υ

c

Ή «

Ua •ο >»

-C ω

« ba

Ό >>

C £

§ ι* <— ο «ο -a

-S 3 χ Ό 3 CO 1 § «1 > C ο ω X ba s ·°

- § W ^Λ β >—· ®

ο °· & 2 ea 9 C 3, ΰ c I

C (*~ •3 fi ‘3 60 .Ξ = « 2 _c — ^Λ •3 C

Ο

UT;

‘«aο cr.

Ο.

α <

ΙΠ0958

AP. Ο Ο 5 7 8

X S 2 5 S £ ~ S s·/	-68.0 (c=0.5)	-40.5	(¢=0.5)	-41.4 (¢=0.5)		-26.7
Λ >
9 I	«η Sj ,~s m X o	os S3 cn S	x-s	119-122 (toluene/ hexane)	ig I	·—· Ί**» η· X
m.p. (‘ ecryst	τ 2 ε» SR i .¾	137-1 (toluei	X x:	165-1 (iPrO	140-1 (iPrO
u
Ό					Os
13	00	oo		©	r-
[	in		CM	>n	r~
►» '
	00			r—	Os	so
£	*fr	Os		cn	TT
		©		in	©	so
s	00	©			00	so
cn	tt			cn	cn
	o	O CM		%	o	o,
s «	cn Z	z		£	CM z	CM z
g 2	cn	cj		OQ	-t	CM
§ I	CS				CM	CM
X •n	CM X		CM X	X so	X in
5 *“	CM	m		n	CM	CM
	u	CM CJ		CM CJ	CJ	U
e 2?
<£> w?
				(rt	X-*»
S ε	(rt	CC \-s		52-	*> cd	CC
V
	£ ω «	£ ffi		£ ~ Cl UJ		<3
	7'i & xz >—<	y σ £ XZ	7' 4 £	>-Sf		£
	<r&	o~f-	z ff		X-Z r=\ c/Z	χ·2 /=r\ W\ ,.Z
	/ \			/ \	o / \	O /
	w	y^_					y
		/=\			s=\	/=λ
	4 y	Ο		O		v_y
a				s		y S3
	z„			z„	M	M
	I	X		X	z	z
	x Cy	\\ //	_ (\ y	£ I Q-	x
	X 2 S—<	x o >-		x 2~~^	O _Z	o j f
X		8 _><			° -Cf
	°~MZ			°~GZ	\\ y	\_z
	v_z	\\ //		\\ y
X	O'.				CM	cn
ω	SO	r~		r-	Γ-	r-~

ΑΡ/ο/ο 5 / 0 0 7 A 5

P3O958

X ® 2 * i	+ 26.6
► CJ © o w	<n o «Λ X	174-176 (toluene/ EtOAc)	ci 77 «Λ %	53 ω so e c	2° Ϊ3 a? t- c e
u • (Λ ri ε © £	151-1 (iPrO	Λ O iC ω	—1 4> « — = ” i2 S	-r © « «Α 2 χ £ o ©
'w'
X»			cn νη	OO SO	cn
iel %	m
►»
	so		©	©
£			<n	OS	Os
	sc’	Tt	CN	©	©
£			©	C*S	cn Tf
cn
				cn	cn
u	O <s Z cs <s	CN z [£. Os	cn o	o <s	cs
ecula mula	CN z SO CN	z 5s	z C Os
o o	X m CN	X ICS	X m CN	X ICS	X m
	u	CS u	U	CN u	(S
Λ ί
tere< mist	z—\ 0£	06	ΚΛ 06	75 06	7S 06
75 Ji					s-c
u
z*s M	A- 1-2 y—(	Ri ,	vl_Q	o	£ | Q Xs2 ΛΖ-ζ-'3
	oK?	<Kiz		οΗί	o^Q
	\_y		\_y	v 7	\_7
		Li.
X“S x	Q. y^uj	r© COOMe	Ri	Ri	Ri
	M	z	Zw	Z	zn
	2	l	I*	X	X
				o
		JZ		\_	/za
	x Q-		( y	/~\	\\ 7
	o y	ό /“ '	x y—'	\\ V	x y—(
(II)	8-c>	u //	θ-Ο	8 °~Gz	8 /=< * υ?-Λζ
	\\ //	Li.	\\ //	v_y	\\ //
X	Tf	V*,	Ό	C	oc
a	r-	r-	Γ-*	H'*	Γ-

g 7 L 0 0 4t>S 0 /d/dV

AP. Ο Ο 5 7 8

IM095X

X S 2 a S £ ~ II ο
•
? 1	'φ' V© c	os S'	Ο Λ) 00 c	ΟΊ Μ V X
	*Τ Si	τ a	--ί «	τ ο
ο.	00 2 s© Ο	ΟΊ J2 O' ο	οο 3 ο- 2	04 β V .¾
Ε ί		·—1
U
Χ)
-Γ χ»	Γ*	Ό	04	^1
ω	xt		Γ*Ί	SO
Τ»
	r*	Ο	ο	rf
£	τζ	V		Γ*Ί
	ei	V	ei	•ri
5	90	ν>		Ό
	<η
	04	η		ο
U	Ο	Ο	ο	η
«Β «	04	04	04	ζ
□“a	Ζ	Ζ	Ζ	_Ο4
ο e	04	04	ο	CJ
« £	04	04	04
ο ο	X	X	X
S 5	«η 04	Γ- 04	η 04	X wn
	Ο	υ	U	d
				u
β e*
β ΰ
ς> ώ	t/i	(Λ	to	co
11	» αί	ΰί	fitf	oi
3ΐρ IS			χ—»'
	Rs,	SL·	RS	£ 1 0
				^Gz °
		\_Γ8
	\_y	X	ο§	\_7
		υ
(III)	R	Rj	R-l	R-l
		ζ	ζ	z
	X	X	X	X
		χ		o
		χ α.		/
	X χ:	Q /	£
	ΙΟ ο-		X α.	/ \
		8-^ Ζ/ζ	ο Γ=^	\\ V X >—<
X	ϋΜ2	/ Λ.	υΛ_/,ζ	8 /=< 5
		V 7 Ο	ζ““\	O—G z
	V 7	'—' Ο °η		V //
		I Ο		\\ //
X	Οι			• · 04
ω	Γ*	X	90	90

P3O958

X » - II «	r- 1		-28.4 (c=0.5)	CM CM +	(c=0.5) _1
► rj o o w I §* ε 9	140 dec.	O u oi a Σ 'w/	182-184	u < 2 £		v> oi o 7 C4 oi A oi ri		122-125	53 § X ω JC	2 £
u
e /-».						\o			sO
3		©		Oi
	X)		Tt		>o			o
►»
		X		l		O'			O'
£		OC		«ΖΊ		Tt			Tt
		oc				c4			c4
S		Tt				oc			oc
			Tt		fO			rc
						Oi			CM
u		o		O CM		o			o
a es		<m			Oi			Oi
ecul mul		2 Π o O οι χ		z Oi Oi		z Oi Oi			z Oi Oi
O o		x ·		X O\ Ol U		X			X
s a		ΙΖΊ CM			25			v*> CM
		u			U			(J
e t·
8 w									^-S
ter mi		OS		1 1					oi s»/
c« Ji
u
	δ	HCI
	b	2 8 .	s	-£	£	~4 OH	X Q.	s	^LU	£
M	>	IQ CL	xz		xz /=		xz
	zz	-432	o	’y-	z h	° r	Z t/	a	—(\_	v2
		\\ //			y		t)		(\	z/
	X
	0 >=\	OOMe	/=\					/r\
M	o	y /)			\=z
a	A		_/F		>1 UJ			«UJ
	> z	ί O	2 N			z		z N
	x		X			X		X
		£		JZ		I £		X	JZ
	X	Q_	X	(L		x O Q-		X O	0.
	o o /=		OO			8 /=(		OO
s	° V-	Z Λ	υΎ	Z Λ		°-4_az		° y-	z ft
		_y		j)		\\ t)		(^_	t)
X		CC		Tt		w-i			<5
Γ,Λ mU		oc		OC		oc			oc

L rc

CLT !O έ

a c

IB0958

AP. Ο Ο 5 7 8

ζ-*ν X ο 0 5 S « - Β S.Z	-50 (c=0.5)	- 11.2	(¢=0.5) — -- »
X“S
►
		35
U ζ ο *®	ci o	δ x
U • V) R· £?	m Q- <N f±	33-1	- 2 .¾ &
ε ν 2
σ			26
	© Γ
►> '
	in
5:	’’«t		m
	ri		in
	^4		σ>
		<Ti
U			o
α β
3 3	2		2 VT
ϋ ε	o Π		CM
I ΜοΙ for	X W) <N u		X so eg U
β £·
S Μ	/*S
ter mi	az Ί*/		az '•s
s, he
u
	£		«Γ
		q	2 z <M X ’° £
s«z	xz kr\	xz	/=<
			r~Gz
	o	o
	W
	Q 8	<Tfc	«Γ s
		zm
s»-'	>.o	)	»l O
	Z.	z
	X	x
	X x:		X
	X O 0-	X	0.
		o _ o /=
	°m2		z A
	v_y		_y
X	Γ		OC
ω	00		OC

ω

J5

C «S *£ c

ε *

ο

Σ £

C £

ο ο

a

S je ε

.δ

C (Ν

Ο\ t

(Λ ω

Ή.

ε (β κ

ω ω

Τ3

C

Ο

Ο.

ε υ

_c

Η ο ~ <

C 3 „· ' « « ·β Έ = β 3

C5 CQ h ^ε

I Ό

73 ίΛ ο

c ο

ο.

ε ο

υ σ\ οο ι/ί

JU

Ή.

ε

Λ

X

UJ

U’

Γ* ’ί /\Ρ/Ρ/ο 5 / (1 0 7 /

Table 4

u~

AP/P/o 5/0074

AP . 0 0 5 7 8

Table 5. Analytical and spectroscopic data of compounds of Examples 16-92 ws cn $

•l o

co

Σ

Q

S z

X

X s

s cn u

I?

8s rf ⁸ > ii « Εύ o (Λ s

E u

• •w

Im aa *

>>

c fM s

v

Ξ * X X z-s cr cr

Ξ ε\έ ©

Ό — m £ r/ ^r· * έ ί oc

X rf

Ό *r· —— © “ CT © 00 3 Ui

X «

-m

O X

3=. © iiCN mi

Ui

X rf ©

t>n I X E £ 5

5Λ ,

t— CN 00 © mi ri

-t © “ I = 3 £ t„ xt oo © t οό Ui Ui X X t * ε © πS3 X c— rf -3 X F· <

OC CS Ui rf X *: —· t— © ui X X © —· oc *t ©

© —.* © mi = £ © n © © —'k.*' r— oo rf —; r— —’

X X CN —_ ©* σ © © -.. —.

t— cr cr -c— Tf ©

rX X cn © cr © © so os cn ft; cr oo

X X X cn <1 <*i •o' © ^, © cs r- Ώ © |< cr t~~ x X ~X x

X m *1

S 3 ^ — ©

Cr m A t< m OO ι ..

.. cn © <> X >-i X c- — X · - © cr x 3 3 ”1 © ® Of g rf © © 3 -s ©

© Ui rl 5 x © •Q CT mi X

X cr © x « »S

X n ©* ε' § rl r. x rf X © *1 3 ©

cr

X X <N ir zr © X) © —

X so © t— — cr © m S r.· _ c Os ......

OO oo

XXX Os cn n s ε* ε* cr cn © m m> Tt © © 2 t— ri ©

So ©

X $ · * 00 X

OO CN • ·>

rX ©* oe ©

© ©

ri rz* Ό n

m •o ni n ►»« ri ©

in ©’ ©

© c— cr <n cr

Ui ®

X cn m

Sis © CN ε’ ε'

CN rtTf ©

n

CN cr rf oo ©

cr © m m> © r- m oom rf © m cr — —

X c

Tf

X rf

X S 8 r* ri cr cr cr rf in © cn m cr —« cs © rf © 't cr rt © m cr — —

Cf cr rf r^ r-/ Z Z © cr 00 00 mi mi X* X* •3.* S* m rf r~

3C r~~

U Ό C 3 « C U u.

© rf

CN ©

rf r?

© cr ©

© cr +

X g

cr n

-3· © © rf m rf m cr —i © ri © cr CN © cr —<

© cr ©

© © ^r n m cr —<

r© r-4

Z* ©

© r>’

Z* © oo —I © © so X* X* ©

t-;

3C

Γ •o

U ©

© oc r~

U

Ό

C

O

u.

oc cr oc © m © so Z Z* ©

X* ©

rf

X* τΓ c*, ri ri oc oc u 6 o

U

C £

r~ rf ri rrf rrcr +

s •s^

VO © © © © r- m>

© m rf © xt cr n © in cr —> —i rf m rr cr © © Z* z“ ^* if in in mi mi X* χ“ it ~ © r—

ΓΟΟ ©* •3 iS

U

Ό

C

O

u.

AP/P/9 5 / 0 0 7 4 5

OO cs in l’3O*>58 r-i ©

C-l ^i ©

cc s

Q

Οί z

s

N

X

X © rs s 2

V1 © .. Ρ χ , X cs n — so

X ® rs ε x © Tt -i- © e ·— cs ΑΧ © £

r* OS . · '/i x χ-χ cs X ©* —< ©

CS

M5 S ci © _* I —' © w © X CS _x 3 X &

oo

OC c-. rs £? T C r—

X X <T rs © c © -Ξ r— rs © © cs —' υ

o δ <

^M 3.

9 u © 3 CS o .“ > 4>

Ed ε

w »» ΐ¹ aa

Ed (Λ ►>

«

SS

V

C

Φ

Ξ

X

Cd ©

c—>

cs

ΤΓ +

© in n

r-i ©

© © r— <n rs m r-. — cs © rs — <5 © Z Z — rf* © © r—

X* x’ cn rf © oc cs' cs' oc oc U d =

-3 3 rt C

U u.

cs in ·* *> £ r- cs X ® Zm wm 00 <3

Γ— CS ·►

T X « <s X ·®

X 'd —< © O ”*

OO

Γ' σι

X r-i co © r—ι cs' ΐ X °° ο T • · *

X S- 3 £ cs rx — ©

Oi oo

C-l in r-i ©

© r^

X

S-T ©

© oo cs

Ή

Tics in

C-l +

s x—x ©

OO e-i ©

r-i ©

© m © c-i rs in c-> — —, -— *> X <7; cs X ©* 2® ort x

(- r-i ©

© cs oo r-i σ

Ί © co 't ©

in ίί?

* i’·'* ©

σ (— Ai Ai X ¹ 3* ~z ε © © n —' in

X ί gx \O © — © in

Γ~;

C-l

X

Λκ *o x s — 1©

X ci co © ^. © χ-- t~~ r-i s ~ si *> © X

M3

Tt •n cs x

C-l vi -£

X <* X Oi —t © © SZ X rf- CS

Si . σι *S © I — © © © r-:

OC

X —

m ·° r—i © ©

rs X — ci in -J X

X oi -1 © © © Sx

Tf CS

2¹· ε

X Αί i x © Ί — © — © _.

oo Jg X *?.

= — . 00 3 —ι Ό .

Ai oo X rΪ© © σ 2 © © c-i r-i r\ z“ (-;

z

I© C-l r-> r-i © \© X* x t— ©

m

Oi cs — OC 00 U U © c 3 rt © (J u.

© cj rs cs

OO <N »r>

+ g

©

C-l ©

C-l

1© ο n \O r-i cs m C-l — © © r-i m (-; z* ι© Γ~~ m m 1© 1©

X* X* r~ © © oo cs’ —i X X

C ϋ rZ ©

CJ ©

c

C tics ©

© x-x

C-l

X rs ((CS (© f-1 +

s x-x ©

rs 'ίAi χ X rn

Ί Z. © cs

CS c-l t— X A< X X -. ε — oo

AA rn = sr £ ο © n r-i r- in rs © oo © cs © r-i —<

rn

Tt •-t tjt+ © © Z Z* © in rs cs in in X* X* cs <x CS 00 r-i cs r* t— d d ©

o rt u

C

u.

Tt

CS

X x>

3J

A X

Six f x

X r-i

- ε © 2 © Τ' τι- χ

- τ x oc T °i

- ?. ε ©

oo in rs

Ai T X Γχ * z^-*\

X

X

Ό£

Tt m

X ©* (— cs . . Tfr rs © oo 2 Ai ©

RF. 00 »JR

-- t©* Ai in

Tf © <s oc oc p in 00 2 — ©

(oi ©

Ό x-C

- X r-i co •n

Γ© oo cs ©

r-i tn +

g cs ©

c-i ©

© in in tjcs η c-i —I m σ r-, — ©? © Z Z rs © σ oo in in m oc — CS ©

© ·->

CS oc rt _ U Li m, cs

Ο rs cs ©

n rs in in m

+

-rt^-

Tt in in xt σι r- in © © rs in r—, © C-i — © σ (- © ©_ z z rs © \O © Tt rf η σ Tf —; cs ri r— (u d

U tl cs ©

in

AP/P/ 95/00745 ©

c

AP . Ο Ο 5 7 8 oo

P3O958 *

tc ο

tn

S

Q

OS z

X

N £

s s

fC ri. © ΖΓ E 8 a cm ⁸ >

• Si

Μ V ω

«5 ε

w • »s ca te *3!

a s

a e

V

Z3 i ·* £ £ ° X so

X 'O £ r£

CM σ

tc oo £ «η t

WM °° ™ $ X £ £ r~ « X 3 £

S’

OC S-/ £

— r3 6? © “ X* ·ο

Os

CM «η r- ο

Γ—

X.

£

CM

73* £ £ CM CM 73 73* •Ο 73 ι-~ — - tr t2 t* <*>

• ♦ ·> « *

OC >***

X £ £ χ H *O *»

42- © m oc A r* iz)

OC As Λ-ί χ 5 = £ χ x <>i ε -5

2^ cc n cm ** r- in ^x 4 x £ X £ r- —

X cm —r CM 2 os' 3 ©

CM

CM o

te —z Os q oc ,

X ⁰⁰ CM <7 3*7 © Os “ χ £

CM *

© ©

cc oc x~\ H— £ £ X ε s

7Jin i-C cc

SO σ

CM f-C

Tt

CM ©

η- χ

CM CC /— OO £ © <1 o © x 3 χ

CM

S ε

CM

CC

CM

Λί £

n «X 3 έ £ tb tc • * Av

S*^ X o © o

— CM so OO r— so X χ n

X s

V_z cm

.. r= ί χ 3ί“

Ο O. £ Γ*· c —; C co Oh s-z , .. £ © © cc so £ x £§s £ -^ —

- oo .. 73 q

3^ ft ·* « r— P cc £ 3

Γ·» **1 © x 2 oo £ ^ ·γ — 00 © 73 ^ © ^ Γ- CM ♦ * , ·

X X cm, cc © Ό te* —« in oo © cm -—r- cm xx

S S 5 £ MS cc oc © £ r— m ©

oo ©

oo © Ό £ cc ~ r3 » χ ©

Tf oc Av £ ©

-^CM oc © X © £ t< CM ..

X © '“C. CM 73 00 3 X cc £ — r^ oc r© ©

C;

CC

X ©

oo m‘

X ic

E te cc © ΓΟΟ <s oo

X Κ ? =? t-c « xSg Sri© ’l CM 73 00 3 X oo £ — r© x £ ©

r© te

S

CM

CM tc

CM in ©

’t

Tf cc © m m oo cm m CC —

S?

so so •s as z z ci cc © ©

7t

X

Γ-’ ©

•Tf·

·.

£ cc q © oc © © u u 2 □

S3 u

u.

rCM s

CM • A

CM

CC

CM • *S

Γcc tc +

s— oc ©

tc © © © © cm m cc — ©

©

Γ-χ

Z

ΓTfr

Ίξ tz‘ oo in in m

X X

7}·

CM ©

Tt oc oc r- ru cj

Ό

S u

C a

o oc

CM

Ίί ©

CM ci tc

CM

Γ-’ tc tc +

s ©

© tc © O in m © m © m © © cm in cc —

Tf CM so © Γ- ΓZ* Z* in © © © so so

X X cc © © ΓΟΟ oc u u jy rt u

C

O b

CM ©

CM •n tc + Γ»

S CM © SO -H Tf CM mo© in sf <r r~~ so m © m © © tc oo cm c- in cc — —

CC 00 oo © ©

z*

Γz*

Γcc ©

Tf in in X £ oo oo © oo so >ri r- rCJ υ

rt

CJ

CJ

C

C b

C.

r<M ©

7t

CM m

tc +

s g

tc ©

cc ©

© © cm m cm in cc — © cc tc CC

Γz'^-

Γz © 7t cc cc SO SO

X X oc ci © oc ci X oc oc CJ CJ 3 *

C3

J oo tc

CM

SO ©

CM

Γcc © tc cc © ’S’ CM © <n in © t— m © © © Γ- Γ- CM cm © in cc — — © © in Tt so © z* z’ in © 7t rf

7f

X oo sn u

«

CJ

CJ e

£

CM

CM $

CM m

CC © «η © cm ^3 in cc —· —

CM oo 00 00 so so z* z © 7t «η in » as £ £ ©

7t ©

rCJ y

Έ

U

TJt~~ so rO rc c

>n

Lf

ΛΡ/Π/ o t2

Λ ©

Λ x*i

Ο w

S

Q as z

z

X u

<

d v

v © u 9 3 CN O

T >

i. <u u © —- rco s

ε u • ·* u

aa *

se ►» «

e a

C ii ΰ

X r-l

X ©

Tt

X 'R X r~ — ©

°°‘ X Ai cn = ε 3 ’R ” ri . ι 00

X ©

•^· οό . Tt

Ai © X μ

CN . _

X

CN ~ cn ό oc 3 Ai Tf

X « — t-.

”

X ~ cn ~ © 25

X cn

X

CN © ©* © cn

X ε cn

X. Γ-; r-i cn it ©

CN

CN cn

CN t-R cn cn +

s

NwZ

CN

X!

CO

O WO Tt CO r* wo o wo cn σ> CN sc CO —

CN

CO

Z~

CO CN z

rWO W->

DC

Γ•o

X

ΓX

Γ-;

L· •o

n.

z-s X

I

-μ r— siS oo . Tt CN oo a;

Ai 3= w X “ E .

^S - X r~ x cn CN pi ¢/ OC ¹ X >©

X ri

CN ©*

Tf r-i

X © © £ X

4έ pi oc . - 'R

CN

CN oo © .· CN

X rcn = X © - -1

3 3

Ai O oc *r x . ± c<

© “ cn

S -= ε © .—- — ©

©

CN

ΓΓη + cn © © z <s © oo* cn cn Tt CN © © © X © © Γ- X X © © © © Γ- X CN © X

X

Tt © © z* z*

X ©

T T

Tt © x X*

Γ-* CN © ru u ©

c o

IA

X, cn © se © X oo r-

r.Mei 5 3 £

- ri cn 3 A » ” χ r- r© t X T

X <n X © Ώ ES © — ©* © cn ©

°° Ca; 33 x O X Ό .

© si oc X x £

ΓΕ ~ ε © x

CN i E

Tt ©

o

OC ” ® © X ” ri ”1 Ai -- © X ~ © ft © O © r- © oc r- X *T r: 3 8

X 3^N.

spS

Ai E £

ri cn oo cn

Ai χ Ai X ~ x . © —

3©*

CN © 44 ‘R OO © rZ—S >—*N * »

X *T* r-i cn cn X x © -i cn cn © c —-

	w-M	W>
Tt	X
	ri	X
00	Tt	AT
	©	X
X	r-’
3	X	©‘ ©
00	-	oc
CN	“O	CN
©		ri

oc

A © x 3 cs — X 00 ~i Tt t

Ai

X —· oo ©* T 3 © X ri Ά .. © X — © © *> t ©

CN 00 ri X Ai X CN <N ε ^Μ· 3 © ©

CN ©;

OC cn oc c’ r* <n <**> _ s 5 ? ε€2 - x wo

X — rt ©

Γ © ..

x °° X x σ cn © ri 3

Ai cn X O cn — 3* E* cn © X © ©* © x cn oo S Tt

X X

ΓΊ <N +

X

S

X

CN

Ν’ © © © «t Γ- X © © © Tf cn © cn — © CN © © © © z* z* ©

r—

CN tX X X* x' ©

Tt

Tt

Tt © © r— rd ϋ ©

— — 3 C U ia

Tt ©

CN

CN cn

CN

Γ-* cn cn +

s ©

oo cn ©

©

«. ft. o ii i,-2 ^c. I §

Τ' <U 3 «i e ©

SE = se S C u* t—' S3 fe $ 2 E r* r* co ci oc

Tt s

co —M Q\ x cn r>

uAP/P/ 9 5 / 0 0 7 45

X X cn Tt © x © © © © cn x cn — © Tf cn cn

Γ·z‘ rz‘ © © cn x © © X X* oc ©

CN

CN CN oc oc U U ©

c o

u.

ΓΓη ©

Tt ©

© x © © r- © © © © X CN X r*. —>

© © © cn cn cn cn r- x cn — —· rZ* ©

ri

Z

Tt Tt © © © © X* X* ©

CN

CN

OC c

© _o ΰ

Tt cn

CN

OC ©

o ca oc ” rCN © 00 00 Z Z* cn © © ©

Tt

X*

Tt

X* oo x Tt CN r-’ rrt—

U U

-3 *°

U ^C 3

O U IA ©

c

-= 3

PW58

ΑΡ.Ο σ 5 7 8 *

CT ο

e at ζ

X

Ν

X

U o

§s ii «>

* 411

M « tt © iw>

tt *

to s

c <u

Ξ τ τ ηϊ«

Γ- —- _Γ

Λί 3

X VT © © © © .. —Ζ ζ—>

ο X Γ— ©

Λί 3 X 00 —·_ ⁰⁴ ©, X

X

CM cr cr

X

CM cr

X

CM

S' ©

rf

Os

CM

ΓΟΟ cr cm s * x <m X © © x

S-Z S-Z © © © ©

X C— CM O

Os oo

CM

4.

Os r— cr + S 5$

OO rt © Γ— rf CM vr cr ©

© © vr vr cm vr cr —· © © 00 Os SO so z z — vr Os Os ©

x’ ©

X*

CM CM cr © cm’ cm oc oc ύ u ©

S u

Os cr ©

cr

CM ££ o r © © —' 73 cr oo vr i<

.. t—

5£ ©* x-z -o © os vr i—

.. pX cr «5

CM

Os

CM

X z< X x © S © —I — © vr —<

ϊέ = o r

--Z -O vr

Os —

Γ—

X X 4 —' © © ’—' cr ao (— °°

CT. X vr . cr ©

CM X © © CC © t—;

Γ— X

X X

X ⁰⁴ — © ³ 3 © <—

P—

S x x X X °i —I ©

3© © T

Os I— Γ— X x X X ’t ε

S— ^z

-° Os © rf rt r?

Os © 00 Ά .. Γ— φ

C7 Ϊ vr cr ©

X

CM^

ΣΓ ©

©

Os

X cr ©

cr

CM

- X © cr

3 cr © t— —I rt (—;

cr

X “E X 'T ” 50 © ' OS vr oo © cr . Ζ Z— x5 I © —z g * 00Ώ Ϊ =

57!

- fi © fc © 1-Z rt £ cm cr oc (γ

X oo —— © © X x © 5 = r— *

L· © 50

Os s—z rf vr δ;

cr vr cr vr ©

vr ©

© © vr rf cm vr cr —i ©

CM ©/ z*

CM rf x‘

CM ©

oc ©

U ©

¢3

V

Os ©

Os’

CM rt cr

CM

CM ©

CM (— ©

cr

CM

CM ©

z*

X z rf

CQ oc vr

U ©

c

Os i-T

CO ©

rt

Os vr rt *5 ° © rt cm vr cr —<

©„ z

© ©

©/ z’ rt ©

© 5;

[— ©

ϋ ©’ _r>

U ca

CM © © -¹ ^⁴. —¹ (— 2 Σ-r 02 x

U ©

CM rf +

^-z ©

CM rt © © © CM (— © © © © © © CM cm © vr cr — — t— — © © so so z z © Os cm cr © ©^ X X »u *CN ’τζ rZ r- ru u ©

_u

S u

© c

o

X

C, rf ©

Os f c—

X © *“

3

X Os ”1 © © x£ = «> _ε 3x5 — “ cr r~ ^t ©

oc ©

X vr oe . ©

X oo

X (<

X oo Ί — © oc 2 X ΡΧ =» — r© X © = 00 . o 3

CM rCM

Icr cr +

>-z>

© cr rt

X CM © τΤ in r-^ rr £3

3“ cr © © vr © Os CM r- vr vr © © © © © © vr © CM © © © cr —« — —

CM —· rf © © z z“ <N —' <5 'O Tfr Tfr cr rf

ΓΟΟ

CM ©

_o =3 3 U X rf rf

CM cr

CM

C—

X rU £

P- rt cr © cr cm © © cr cr © © © © CM Os cr © cr <—' rt —< © © so © z z © © so © vr © X* X oe cr © — rf rf oc oc u u © c 3 « C

U u.

© rf

AP/P/ Q ΐ / it 0 7 4 Ί u u ©

c

ϋ £ Fi 0 co 5 Q Qi £ z N 2	10.15 (d,lH); 8.30 (dd,2H); 8.18 (d,lH); 8.10 (s,lH); 7.98 (d,lH); 7.86 (dd.lH); 7.75-7.42 (m,9H); 6.21 (m,lH).	9.24 (d.lH); 8.07 (d,lH); 7.97 (dd,2H); 7.76-7.70 (m,lH); 7.62-7.51 (m,5H); 7.46 (d,2H); 7.39 (dd,2H); 7.29 (dd.lH); 5.10 (dt.lH); 3.52 (s,3H); 1.82 (dq,2H); 1.00 (t,3H).	(353 K): 8.90 (d br.lH); 8.00 (d.lH); 7.70 (dd.lH); 7.567.42 (m,9H); 7.38 (dd,2H); 7.29 (dd.lH); 5.13 (dt,IH); 2.72 (m,2H); 1.90 (ddq,2H); 1.00 (t,3H); 0.90 (t br,3H).	9.20 (d.lH); 8.32 (d,2H); 8.08 (dd,2H); 8.06 (s.lH); 7.82 (t, 1II); 7.65-7.40 (m,8H); 5.00 (dt,lH); 1.93-1.73 (m,2H); 0.98 (t,3H).	8.32 (d,2H); 8.16 (d,lH); 8.10 (s,lH); 7.88 (dd.lH); 7.71 (dd.lH); 7.60-7.42 (m,9H); 3.86 (s,3H); 2.56 (s,3H).	9.72 (d,lH); 8.47 (dd,lH); 8.15 (d,lH); 8.07 (d,lH); 8.05 (s,lH); 7.96 (dd.lH); 7.81 (dd,lH); 7.71 (dd,IH); 7.62 (dd.lH); 7.53 (d,2H); 7.46-7.36 (m,3H); 5.78 (d,lH); 3.78 (s,3H).	9.70 (d, 1H); 8.45 (dd.lH); 8.18 (d,lH); 7.80-7.38 (m,l IH); 5.83 (d.lH); 3.79 (s,3H); 3.20-2.80 (s br,4H).
MS (El; source 200°C; 70 eV; 200 μΑ)	406 (M+.); 386; 232; 204	396 (M+.); 367; 262; 219	394 (M+.); 365; 275; 260	400 (M+.); 371; 232; 204	411 (MH+); 232; 204*	402 (M+.); 343; 238; 210	422 (M+.); 258; 230
1 ** c u • ·* ca Oi	3300;1655; 1590;1540; 1500	3250;1635; 1550;1500	3250; 1630; 1540; 1500	3270; 1645; 1590; 1550; 1495; 770 _1	1750; 1640; 1595,1550	3290; 1740; Π 1640;1590; 1530	3250; 1750; 1660; 1590; 1520
tfi Β» s JJ £	Calcd. C.70.91; H.4.22; N.6.89; F, 14.02 Found C,70.86; H.4.17; N.6.92; F,13.88	Calcd. C,78.74; 11,6.10; N.7.06 Found C,78.72; H.6.10; N.7.01	Calcd. C,82.18; H.6.64; N,7.10 1 Found C.81.93; H.6.64; N.7.05	Calcd. C,74.90; 11,5.28; N.6.99; Found C,74.67; 11,5.33; N.7.03;	Calcd. C.76.08; 11,5.40; N.6.82 Found C,76.16; 11,5.42; N,6.84	Calcd. C,68.64; 11,4.51; N,6.96 Found C,68.52; H.4.53; N,6.94	Calcd. C.76.76; 11,5.25; N.6.63 Found C,76.39; H.5.25; N.6.55
X		47	OC	Tf		on	52

AP/P/ 9 5 / 0 0 7 4 5

AP.00578

P.MW58 <r ©

cr •S o

vi

Q ai z

E

WN

N u

o <

4> ΖΓ

Q © fa © 3 <N O .A“ > M « ω © '-s l— Vi 2 ε

V fa tt

Vi

To ►» «

e a

— c

4i

Ξ

X '•-l

Os

Os r- χ cr v;

χ

X s© _ x g P * cr

3« J — *7 £ oo °° —· . wr © E (fa v, £ X H d x Ή — © X Γ- -ο X

Os fa ·- 'δ 4= Ε γ— ~ - Ν fa Ο <Ν ·° X <·

5Λ .

—!Λ —

0C χ *· § ^— . ν.

— [fa £

V.

cr

Os

CN

CN +

—-ζ V 00 cr © 00 ν> rCN Ό cr — * © © © — Tt © Tt Γ- Ό cr — — θ' οο © © ζ’ ζ* [fa OS* os. ©

Tt d * 0

Ε Ε οο θ' cr (~~ (~~ ο υ © 2 2 ο « C

U t cr

V οο V)

AC Γ** *τ<

Μ kdW *±- cn

Η. Ε » fa · χ

Ε -ό cr ^χ r · · — Η χ χ ώ X £$ ·°’ © X X ©

OS οο . -ο vs οο —' ..

,ΐί οο X f© οο X £ r4 «*ι «« χ ,ε £ SO cn « cr χ 3 > χ © rE A 3 _, oc c~ © x — rr χ e ~

• Ο Ό

0\

X o

φ

CN

Tt O' -rj· cr cr cn vs vs m oo r~ v vs © Tt cr cr so vs cr — —

CN 00 Tt cr © © z z

VS CN CN CN Tt Tt x' x’ © oo V, Tt vi vi sC Ό u u © Έ

3 ” O U u.

Tt

V,

E CN

- Tt

X S X — CN $ S

- H • CN oo - *> CN

X 00 ►fa it o •d x <2.

* X E

Vi oo (fa 2 <N © ™ —· oo Ό χ r-i CN ·.

X *► cr 2 oc 3 x £ — t~© X © £ ⁰⁴ —oi 3

X v

Ό cr £

O' Ό SO OS. vi —

I

A< © E -. cr cn

Ms cn *SM

CN CN cr vs [fa CN © Vi a

© © Tt OS CN V cr —

Os V \© so (fa tfa z z cr cn Vi Vi vi vi Ε* E* os — cr cr ci ci oc oc

J u ©

_C)

U ©

c o

to v,

V

CN ©

oo X ·_- E E

X Ό

Ά Ό si —

·· X 'fa· 3f

Ϊ.6© fa' CN Tt <η rS3 χ ri

CN . 3 E

Ό

O>

»x~ © ® cn cn £e ’C’ y ό ε .

© • ·> E r— X X

CN vi

-.3 3 oo Tt 3 V Ci [fa X

X E Ε H

—. Vi os.

rTt H Ό [fa χ ©

CM

X ©’ 'w'

E

CN ©*

E 3

©	•	CM	CM	©	«-Μ	oc.
cn	Ό	_ *	ci	©
00	Ό	C*	*7*	00	©	wS
E	CM 00	E d	1.48	H);	CN 00	X V, ε*
©*		©* ©		d.l	[fa
'fa-'-	*r	sfa*z	X		E	'•’’fa·'
Cl		O'	CN	Tt	sC
	*	cn	ε.	[fa		cr
Os	Ό	[fa	O'		[fa

CM

CM cn

CM cn cn +

cr © © Tt Vi © © r- os CN V, cr — cZ v

© rZ

Tt Ό so so O' SO

E* E* ©* 0s* CN CN ci ci oc oc u u c

Ό o

U U.

so

Tt

CN

V cr +

©

Tt cr ©

CN

00*

CN

CN © V» Os (fa vi © Ci © © Tt cr cr ό v cr — —

CN [fa [fa ©

Tt

Tt

Tt

V V χ' E* do ci © Os SC vi (fa [fa

U U ri *§ a

C u ti.

[fa

V,

AP/P/ 95/00745

V,

IM0U.S8

CO ©

co

Ο co

Ο sd

S ζ

a

Ν a

S co η

© οό id ~ a £ °i a 3, <3 s?

oc Ai - a as X -. ε © —' —' CN rf UO γr— o

oo οο ©

rf ©

x a a <*ϊ —uX © © X-< — rt © A. OC uo — Ai M sc a ©

X

-> CN V ©* 00 © 7Ϊ ©

Ai uo a i<

a CN a

©

CN OC

Ό ©

CN

OC a' ° a co cn a © ~ © a oc a OC 0^ £ © rj e

O' — Γ— -—· — © oc ' so

AC © a

co scs

CN rf cn

AC a

co

SC co r— a a — ©

CN

CN _ tAC SO a t<

uo a

uo © CO r<

~ AC t a

— a ©* Γ4

- © © © © — OC uo

Γ-;

CO

X er sc

Os

OO

CO ©

©

CN a

CN

OS

CO

SO ©

OC co uo

OO

OO CN a ·?: = t, •ό a 3 r— © — © oo —, .

AC so a t-/

CN . 3 a

X ”1 CM *3 « 3

AC © a °ς —¹ r3 a = r— .

_· U5 Os ©

uo a

CN ©

CN •“M ra co a

co sc

UO ,· , .< oo . . At 7 a © ©

SO © ε = R

OO 0 T_* a

F5 r©* a 3 a <n a 3 © oo — a t— sc AC © = s ©

©

CN

I ©

CN a

CN ©

uo

CN

SO

CN = £ . rf © C

3·

SO UO cn c3Ϊ 3 « © AC SO a

CN · 3 a ©* 00 3 AC oo

Ξ P © AC a © a

SC © —gS a

co ©

© oo u-i

AC a

CN ©

rf ©

© a

co sc

SO ©

uo co r— so rf

Csc a e © Ξ °i uo 3 -3 5

Os A © CO a

— ©

© oc a

*«* ©

ΓΟΟ* a

©* f— ©

r— a

©* ©

© oo ©

© uo

00' a

CN sc σ*.

sc a

CN © ©

Ca a ε π

SC SO co co Γγ sc

Tt ΓΟΟ

C-. 3 r3 uo u

o u © C o 3 CN O .► « > a ® u © ---1cc 2

Os

V

CN

Λ uo a^- r— r- cn co co CO CN

OO

CN o

CN

S

Q • *S z*\ u

aa cn ·« ίΛ a

e a

© © uo uo so uo

AT UO © § SO CO a so uo co — © © © so Os tJCN UO UO «Τ'. — — © CN © © Ν' OS rf t- uo os co

CN •N so so z z' os* uo CO rf «Τ. o uo SCO

CM

9C ri

9C u u o

c 3

Z>

Ο ο9C ir,

CN

OC os rSO so z* z ©

rf © N uo uo

OC — © CN

ΓO

C

Xi

CN

O

CN

Γ-*

SO — CO Os + OS s s sO rf CN CO Tf CN © © UO Os r- uo © uo © ©N-CN CO SO UO co —— *—« ruo oc rf \O ©

·. ·>

z z c? o CM CM Xi Xi

X X <M cr? CM 90 (Τ', γ-*· (Μ

Γυ υ «3 ΰ U•V ©

CN

CN* co

CN

Os*

Tt

CN ©

CN

CN

TT

CN

CO uo co •^r <M <6

CM

OO ec

CN

Os

CO +

s <M +

©

TjAP/P/9 0 0 7 4 5 © © N UO so UO © © co Os CN UO CO — rf © r- ι< Ζ Ζ s© 00 so SO a* a'

CN 0 <5 ;

CN CN OC oc U U « _ U IA

AT © © g Γ- Os a so uo

CO ~ —¹

I . * . .

© © © © uo N UO Γ— so CO —· — © uo r~ t-; SO SO Z* Z © a oo ©

Na*

N a* © © oo oc

CN

CN

Γ©

CJ

Λ _ U CA

CM uo © CO OS r- uo © uo uo uo CO SO CO —' © >c0

CO co so so Z* Z oo © uo uo rf Ν' a' a' © co

Γ- ΓU U ©

_u rt u

T.

u u

X oc

P3W58

AP.00578 c

in *>

co s

Q ai s

z

U g< © 8 0 fa © 3 CN O ·“ > X « u © t**

CZ5 fa ea ad vs >>

«

S β —. S u

m

V

Ξ

- © 3 cn cn —— J— oc X Λί x M (Λ CN -- «η sn foc' x 71

g. χ © -- x

-·© ⁰⁰ so 3

X f² ίη ± X CN

X r~ -o —. >Z x s 2 H H cn 0 © 2 © oc 3 <s m

<n + s S 3

SO CN so cn cn cn

nt sC

I—

Z in ©

\C 'S z • * Γ© SO v

©

CN

CN

OC

3C u u ©

i) ~ 0 υ uCN χ έ

X CN / 3 r \O {<) A. o-2? 2 » ®1 ^w -- —— X X Ai

χ. x ε c

Ο (Λ _ it ο so

X

CN ©

©

Os

CN

SO cc <n ⁰ - cn

1- cn nt ..

5; X χ ^χ· x S' - «Ί. cn © x © _’ © Ξ os 00 CN - — OS s

CN

CN cn

CN in cn ©

cn r— © so «η © o CN OS cn in cn — nt c— z‘ sC cn fi Z sO so cn cn so so X X* r-“ in © — CN CN oc oc U U © c 3 ©

rt u

u.

in •o 2 s«n CC cc r** in r— in x r— X x

5-m ε © -rt in r— cn so

SC

3Ϊ η ©* SO © © x r-~ X <<

C X t/5 ™ '—' J. © “ CN SC

X — C— crsO

X £

© sO

X wM ε

ΓΟΟ

SO

X X \O X * cc ε «ί

CN so*

X © X 'P —- f~ © X

CN 5 CN . 00 3 X nt

X » © X Sx © cn © oc 3 X SO X » rt tin ~ in . «5 3 t* x —_ oo © = t- . -,· «0 Os

Os

CN cn

Os

CN

CN

SO

CN cn in cn © © © nt cn so CN so m cn —< — © © © so in © cn r~ so cn — —os m © © z' z‘ rOS nt

X* ©

Os nt

OO CN SO © rV ©’ a>

U

ΓU ©

X

Γ-;

in

X cn

SO cn .- r— r— nt rX

CN ©’ nr in

X X cr X £ in © cn ©

© cn in ©

nt + t—

Sen

-- 71 nt CN so rnt CN m © in os r- m © in in © cn cn cn so m cn —· —

CN ©

so z‘ ©

©

X cn — in nt Ό u ©

U nt ©

in

Z* in ©

cn cn x’ ^cJ- in 0s’ x Ώ u u

© c

£

X X

5? S

1-. u, cn

3

X X 00 χ ε ©

X <n <λ m X

CN cr 0C o X f· X X CN x ©

-o m no cn ^x Ξ = i χ x

X —

CN — toc r— © © OC

Ό

CN

X

CN ί

Os —1 in oc r- CN x X

X CN CN © o © «5

OC © cn so r- —<

X X

CN CN © ©

X X

CN CN

Ή x

S «= r— ——* r— ©

.. 00 x τΐ =

Γ* -a <> r* 00 ϊίϊ . X cn © X x — in

- ε

Os © ©

CN

CN cn

CN cn cn

CN in m

CN r-7 cn cn nt cn c cn cn <N

CN in cn + 00 — Os' OO —-. cn cn ur

-a·

Γ-<x rm .

LT

C‘

6’

0~ m © cn cn © so m t—* —' t— © © in © © © cn m nt cn — — © © cn cn so cn © © © © so © nf CN SO cn cn — — © © © —‘ 0 z* z de ©

O rt sd so

X x’ t-;

X m

nt oc’

Γ©

-J rt

U £

- >

1*30958 it <*>

© e· o

CZ3 a

a z

X

W<

X u

o δ <

« © u © 3 cm o * > M « u © t*»

CZ) ε

u • *» u CQ *

ΙΛ ►>

e «

c

Wi

X χ X x w _T tf-b OO

Ov

X

X © X σ'

W Ό OO

r.s

X X © — © -3 wM x Ώ. 3

Γ— ©

r— cc

X

CM ©

©

CM t—

CC cc ©

CM © oo © cc rt CM cc ©

OV

©.

z'

X wi r— ϋ

υ

U ©

cc rό X f—- cc (— O AC Ov «ι- Ov — O

- σ ss

X X © X .

© 3 —

OC W

-- A X wi •σ X CM

VX *x ε

Ov —r— w

Tt + cc vo CM* rf — -3^- CC

Tt ~ rf CC ©

't ©

©			©	w
Wi			•V	-V
W)			CM	Wi
			ex
	oo		Ov*		—
	Ov		es		rx
	©		©		©
	Z		z		z
	w		w		©
	CM		r*		00
OC 00	wx *T* MM	CM © X	I	Ov Γ-	I	© © 00
•“M	oo*	M·	CM*		r-
u	OO	u		CQ	wx	CQ

t— u

© c

o

Lb u

CJ

U u

© c

Lb

VC ov t—

AC ©

X X — r— te i— ~ X © ΓΟΟ AC AC X ³³ =* x ε © — xfr W,

X γοο 4 AC vO X r—

CM · ·

X

OV CM 00

CM

CM cm © X © CC

Ov oc AC © X AA -. X © rc

X « ”. t ©* AC s =>* r- _;

<*““v

X X 3· — ε ε*

CM ©

* s = 3 ®S

Cv © Γοό AC AC X X X x ε ©

Tt W X t— °° cc AC vo X t-:

CM

X ©* 00 3

AC CM

S ©* AC

S 3

OO t—

Wi ©

© «t w

© © .

X

CM cC C— ,© AC oc X © X © © j3 X oo X x ε

Γ— s—.

CM ©

AC

X se ©

© oo

X ©

X

X ©

X °o X X ©* x

Ί' Wi vg © ''T _—,J r— ..

X X X X X —* ε 3

Tfr

X wS

X AC CC η-ι VO -b ® ©* oo 3

AC CM X » X H ©* AC

X 'tt X X © © 2 ©

©

X

CM CC x 00 X <A X © ©* ~ © X © X

2S X

P ε oo

X

VC © -© © —' Wi CM X OO © x 'T. 3 S © X

00	©
CM	©
00	r— rq	O 00
X	r—	QX
—
©	X	X
	·—<	cc
r*	©* ©	d
Os

a* fik CA ee © S

VO CM .2 « — υ ε

x .2 c o ε oo E CC 03 o

to c o ** · * υ c a υ 5s. s

W) © © w, Tt cc rt CM © W, cc — — © cc cc cc t— t— z z* ©* ©* cc cc vo) ©)

T« <T bt- ©* © © CM ci oc oc ©

_u

U

CM t— ©

CM

CM*

CC

CM r— cc cc ©

CM

CM*

CC

CM (—* cc cc

CM

CM

CM ©

Wi

CM

Wi*

Wi

CC οο

Wi +

© ©

cc +

© ©

cc +

-'t

Tt s*7 £90 /^0 / Ci/ Ci v w w cc cc © Wi © © CM © CC Wi cc — 't Tt © cc rZ t— z

w CM © oo © wi ©

3V

CC cc

OC t—

U U ©

U £, c-, t— (— © cc © Wi © © 00 <7\ CM Wi CC —I

-3- © © w, t— z‘ tz‘

W Ov © © © © x' x‘ 4* oc — ci OC OC u ϋ © ·® υ = U Lb

3· (— © © Tt CC c— © © © © 00 Wi Wi CM © Wi CC — — © Ov r— t— © © Z Z*

CM* Ov* © Wi

4 X X*

W? 00*

X X ci ci c- t— U U ©

jj u

© c

O

U.

w γx

AP.00578

P30958

..5

X f

OC >T _· n O'; Γ CO sC η

OO cn ο

co r· o

cn

S

Q w

X

Σ z

X

X s

<

«

S 9 b 9 3 04 >

Cz3 © O' cn ε

u • * 'b GO Hi

Vi «

c

B oO' *> © oi x X. χϊ E X ’t X B © . C 04 •o n

© cn _ © pi © pi 04 X r X oi e 2 X

-2© — 3 R © oi η χ oi E

X ’T ο ci oc

-- 04 SO 2 O' © 2- cri ©

00* co

As +

s ©

nin m io CO so m © η V © o- m so © © © <5 so Z* Z*

X o η n so so ©

sC

V

O' co

3· •3 _o 3

U ΰ

X co £

>n

Os

O' ri

X

OO • °® οο ρ-, O oi cn X 0© \© '-, . CO ·§ ⁰⁰ O' X<; x X Γ X Ας c*“> Ό X rf co ct v

O' no© V r co O' Ό n ©on © 'C oo cs so n CO —' — © V n n SO so z z“ tri η V St Tf V X* X © x* so oo ©

sC ©

sc •3

C 3 « © u x •3 υ

O' o3 X •o Tl·

O' ε

OO

Γ.3 = 2

X cn rf

V £ H — X Loo Π cn x Ε o E x X cs -1 _r Ό *a £ X H 2 x

X © co. © ε, © ϊ

Τ' ·3* O -3 © °C . 04 •cf

OI ¹ © so OO pin = X £ τί ε.

© O' V O' O; CO ©i O' O' cu 3 H £ τ i = -S 2 2 co ε τί- «

7.^ © © © in c

o w

O o

rt d

o

O

Vi e

υ ”3 ·© X X is- 04 CO —i Ό —> © ©

- oo co

O' O' ©

X O' χ X· X X 2 E ©4 © oc σ °° ε

O' r

SO • «I ec in

C“>

•3 •3 »

2 <=? n oo r-~ X «ri X x X. X i£. co ο* ε* —' x-/ oo <n • * X X «7

Ό •3' 'T •3 O' ..

oi X oo’ X χ ε = O - in 2 Oi

Ό 0 O' O'; oi oi χ x cn <Λ

X (Λ

O'

O';

CO oo X

.. E .

X 04 Ό ”S

S ri oo

X te oo sC oi

X.

X

X xi

Oi

X ©

X

X E *1 2 Ό '•wX d

X X 2

Tf — TJOO X X

X X X E

X co m

oo oo X .. οχ •3

O' sd « *>

-c—\

X co co co x

co «5 •β* ε © in so co ©* O' *3

OC

SC 04

O « — O' g

cn * ♦> m © Tt in <© V © t» o © © © © Ό 04 04 so n co — — © O' η n so sol Z* Z* +t

V

Tt

X*

St

V

X* © © SO © © © SC sc u u •3

U

C

u.

in ri E x co

X «* ©

in + Ch

S ?4

O'* 00 V CO 04 © n — O' —< n co —<

© η n —Ί V CO co so n co <—i —

SO CO 04

O-_ z’ o^

Z* © 04

OO 00 iri ri X* X*

X* ri* η η oc 00 O' O' u u •3 o

C

X in in

V +

X co r

+ O'

S 8

04* _ O' r 04

AP/P/ 9 5 / 0 0 7 4 5 © © so n O' so © n © 04 co co co o~ n co — —

SO O' so so z* z oo oc oo

V

X* x' sc © cn cn u

C c2 g £ s co so n co — © n © SO V © CO O' SO co — — © 04

O' r so so z* z* ©

oo

V

X ©

© ri © v OC 04 04 cri O' O' u u •3

JJ

C o

oc © n r os o~ n © n © r ν n 04 s£> co — ©

o © so SO z‘ z

SO ©

cn cn X* X* cn n

n·’ so

O;

else •3 _υ

U •3

C

OC — 3 |’3()«>SX

© «*> χ·ζ o CA s Q az S z x X S © ©	9.62 (d.lH); 8.28 (d,2H); 8.22 (d,lH); 8.16 (d,lH); 8.11 (s.l H); 7.86 (dd.lH); 7.68 (dd.lH); 7.61-7.51 (m,3H); 7.30 (d,2H); 6.80 (d,2H); 5.61 (d,lH); 3.71 (s,3H).	9.79 (d,lH); 8.30 (dd,2H); 8.15 (s,lH); 8.12 (d,lH); 8.02 (d,lH); 7.81 (dd,IH); 7.63-7.26 (m,14H); 6.52 (d,lH).	9.80 (s,lH); 9.11 (d,lH); 8.00-7.94 (m,3H); 7.61-7.42 (m,8H); 7.38 (dd,2H); 7.28 (dd.lH); 5.06 (dt,IH); 1.82 (ddq,2H); 0.97 (l,3H).	9.80 (s,lH); 9.11 (d.lH); 8.00-7.94 (m,3H); 7.61-7.42 (m,8H); 7.38 (dd,2H); 7.28 (dd,lH); 5.06 (dt,IH); 1.82 (ddq,2H); 0.97 (t,3H).	9.85 (s,lH); 9.63 (d br.lH); 7.97 (m,3H); 7.89 (d br.lH); 7.62-7.34 (m,10H); 5.75 (d,lH); 3.76 (s,3H).	9.15 (d,IH); 9.30 (d,2H); 9.18 (dd. 2H); 8.06 (s,lH); 7.80 (t,IH); 7.70-7.20 (m, 9H); 5.30 (dt.lH); 2.75 (dd.lH); 2.45 (dd.lH); 2.70 (s,6H).	9.40 (d, 1H); 8.26 (d,2H); 8.22 (d,lH); 8.12 (d,lH); 8.05 (s.l H); 7.81 (dd.lH); 7.62 (dd,lH); 7.59-7.49 (m,5H); 7.43-7.33 (m,3H); 6.15 (d,lH); 3.00 (s,3H); 2.90 (s,3H).
MS (El; source 200°C; 70 eV; 200 μΑ)	412 (M+.); 353; 232; 204	414 (M+.); 337; 232; 204	382 (M+.); 264; 247; 219	382 (M+.); 264; 247; 219	412 (M+.); 353; 248; 219	395 (M+.); 232; 204	409 (M+.); 337; 232; 204
1 ε w • * ΐ? η * Οέ	3180;1750; 1660;1645; 1610;1535; j 1510	3210;1640; 1590; 1525	3370;1625; 1525	3270;1650; 1630;1570; 1535	3360; 1735; 1625; 1530	3320; 1640; 1590; 1525; 770	3280; 1660; 1635; 1590
Elemental analysis	Calcd. C,66.89; H.4.72; N.6.24; Cl,7.90 Found C,66.53; H.4.74; N.6.10; | Cl,7.48	Calcd. C.84.03; H.5,35; N.6.76 Found C,83.27; H,5.64; N.7.05	Calcd. C,78.51;H,5.80; N.7.33 Found C,78.49; H,5.84; N.7.26	Calcd. C,78.51; H,5.80; N.7.33 Found C,78.55; 11,5.84; N.7.30	Calcd. C,72.80; H,4.89; N,6.79 Found C,72.12; H.4.88; N.6.63	Calcd. C,78.96; H.6.37; N,10.62 Found C,78.63; H.6.39; N, 10.65	Calcd. C,76.26; H.5.66; N,10.26 Found C,75.74; H.5.66; N, 10.06
	X	rf OC	tri OC	Ό OC	OC	X X	3s. X

a 7 L 0 0 / 9 6/d/dV

AP. ο Ο 5 7 8

I’AINSX

© m

ω

S

C οο «β

Ο

C

C ι— «

ο >>

οό

V.

r.

<

Τ’ κΙί

ΓC

C υ /c/d V

P3i >958

EXAMPLE 93 (R,S)-N-[a-(\lethoxycarbonyI)benzyl]-2-(p-chlorophenyI)quinoline-4carboxamide g (7.0 mmol) of 2-(p-chlorophenyl)quinoline-4-carboxylic acid and 1.7 ml (15.4 mmol) of N-methylmorpholine were dissolved, under nitrogen athmosphere, in 50 ml of dry THF.

The solution was cooled to -20°C and 0.91 ml (7.0 mmol) of isobutyl chloroformate were added. Alter 20 minutes, 2.12 g (10.5 mmol) of methyl (R,S) phenylglycinate hydrochloride and 1.3 ml (11.9 mmol) of N-methylmorpholine, dissolved in 30 ml of dry THF, were added and the reation mixture was stirred at room temperature overnight.

ml of H2O were added and the reaction mixture was evaporated in vacuo to dryness. The residue was dissolved in Et20, washed with a saturated solution of NaHCO3, separated, dried over Na2SC>4 and evaporated in vacuo to dryness.

The residual oil was flash chromatographed on 230-400 mesh silica gel, eluting with a mixture of hexane/isopropyl ether 7 : 3 to afford 0.9 g of crude product, which was u recrystallized three times with iPrC^/toluene to yield 0.5 g of the title compound. **

C25H19CIN2O3

M.P. = 170-172 °C

M.W. = 430.90

Elemental analysis: Calcd. C, 69.72; H, 4.45; N, 6.50 u

Found C, 69.82; H, 4.47; N, 6.48 5

I.R. (KBr): 3280; 1740; 1670; 1635; 1590; 1530 cm'¹. C

300 MHz 1H-NMR (DMSO-d6): 9.71 (d, IH); 8.32 (d, 2H); 8.21 (d, IH); 8.13 (d, IH); 8.13 (s, IH); 7.85 (dd, IH); 7.67 (dd, IH); 7.63 (d, 2H); 7.53 (dd, 2H); 7.46-7.38 (m, 3H);

5.79 (d, IH); 3.74 (s, 3H).

MS (El; source 200 °C;70 eV; 200 μΑ): 430 (M+.); 371; 266; 238; 203.

EXAMPLE 94 (R)-N-[a-(Methoxycarbonyl)-4-methoxybenzyl]-2-phenylqiiinoline-4carboxamide

0.62 g (1.5 mmol) of (R)-N-[a-(methoxycarbonyl)-4-hydrcxybenzyl]-2phenylquinoline-4-carboxamide (compound of Ex. 83) were dissolved in 30 ml of dry acetone and 2 ml of dry DMF; 0.14 g (0.75 mmol) of K2CO3 were added and the reaction mixture was stirred for 30 minutes.

0.093 ml (1.5 mmol) of methyl iodide were added at room temperature and the reaction mixture was heated at 40 C for 4 hour>. 0.1()4 e (O.5 nuro!: · ·: EDCO; and

P3095S

AP . Ο Ο 5 7 8

0.093 ml (1.5 mmol) of methyl iodide were added again, and the mixture refluxed for additional 6 hours.

The mixture was evaporated in vacuo to dryness, dissolved in EtOAc and washed with H2O. The organic layer, dried over Na2SO4, was evaporated in vacuo to dryness. The residue was recrystallized from Et2O to yield 0.45 g of the title compound.

^C26^H22^N2°4 M.P. = 160-162 °C M.W. = 426.48

Elemental analysis: Calcd. C, 73.22; H, 5.20; N, 6.57 Found C, 73.01; H, 5.20; N, 6.48

I.R. (KBr); 3210; 1750; 1635; 1625; 1590; 1530; 1515 cm*¹

300 MHz 1H-NMR (DMSO-d6): 9.65 (d, IH); 8.28 (d, 2H); 8.21 (d, IH); 8.14 (d, IH); 8.10 (s, IH); 7.84 (dd, IH); 7.67 (dd, IH); 7.61-7.49 (m, 3H); 7.44 (d, 2H); 6.98 (d, 2H); 4.70 (d, IH); 3.79 (s, 3H); 3.76 (s, 3H).

MS (El; source 200 °C;70 eV; 200 μΑ): 426 (M+.); 367; 232; 204.

EXAMPLE 95 (R,S)*N-[<x-(Methoxycarbony])-a-(methyl)benzyl]>N-inethyl-2-phenylquino]ine4-carboxamide hydrochloride

0.50 g (1.3 mmol) of (R,S)-N-[a-(methoxycarbonyl)benzyl]-2-phenylquinoline-4carboxamide (compound of Ex. 4) were dissolved, under nitrogen athmosphere, in 10 ml of dry DMF.

The solution was cooled to 0 °C and 0.052 g (1.3 mmol) of NaH (60%) were added; after 20 minutes at 0 °C the temperature was raised to r.t and 0.09 ml (1.4 mmol) of

C Mel were added. The reation mixture was stirred at room temperature overnight, then the procedure was repeated by adding additional 0.052 g (1.3 mmol) of NaH (60%) and 0.1 ml (1.6 mmol) of Mel.

After 6 hours at room temperature, 10 ml of saturated solution of NH4CI were added and the reaction mixture was evaporated in vacuo to dryness. The residue was dissolved in CH2CI2 and washed with water, the organic layer was separated, dried over Na2SO4 and evaporated in vacuo to dryness.

The residual oil was flash chromatographed on 230-400 mesh silica gel, eluting with a mixture of hexane/ethyl acetate 3 : 2 containing 0.5% of cone. NH4OH to afford 0.18 g of a crude product which was dissolved in Et20 and treated with HCl/EtoO to yield 0.15 g of the title compound.

C27H24N2O3.HCI M.W. = 460.96

I.R. (KBr): 1745; 1640: 1610 cm'¹.

MS (El; source 200 °C;70 eV; 200 μΑ): 424 (M+.); 365; 232; 204.

EXAMPLE 96 (R,S)-N-[a-(MethyIcarbonyl)benzyl]-2-phenylquinoIine-4-carboxamide

0.27 ml (3.1 mmol) of oxalyl chloride were dissolved, under nitrogen athmosphere, in 2.3 ml of dry CH2CI2.

The solution was cooled to -55 °C and 0.22 ml (3.1 mmol) of DMSO. dissolved in 0.7 ml of dry CH2CI2, were added dropwise maintaining the temperature below -50 ⁰ C. The reaction was stirred at -55°C for 7 minutes then 0.97 g (2.5 mmol) of (R,S)-N[a-(l-hydroxyethyl)benzyl]-2-phenylquinoline-4-carboxamide (compound of Ex.

17), dissolved in 25 ml of dry CH2CI2, were added keeping the temperature between -50 and -55 °C.

After 30 minutes at -55 °C, 1.9 ml (13.6 mmol) of TEA were added without exceeding -40 °C, then the reaction mixture was allowed to reach room temperature and stirred for additional 15 minutes. u~

The reaction was quenched with 5 ml of H2O and extracted with CH2CI2; the organic layer was washed with FbO, 20% citric acid, saturated solution of NaHCO3 and cr brine; the organic layer was separated, dried over Na2SC>4 and evaporated in vacuo to dryness.

The residual oil was flash chromatographed on 230-400 mesh silica gel, eluting with ir. a mixture of hexane/ethyl acetate 70 : 30 containing 0.5% of cone. NH4OH to afford 0.64 g of a crude product which was triturated with warm j-P^O/i-PrOH 2:1, filtered, washed and dried to yield 0.5 g of the title compound. r \ ^c25^H20^N2°2 **

M.P. = 160-161 °C M.W. = 380.45

Elemental analysis: Calcd. C, 78.93; H, 5.30; N, 7.36;

Found C, 79.01; H, 5.31; N, 7.27.

I.R. (KBr): 3400; 3265; 1725; 1660; 1640; 1592 cm'¹.

300 MHz 1H-NMR (DMSO-d6): 9.60 (d, 1H); 8.29 (d, 2H); 8.17 (d, 1H); 8.14 (d,

1H); 8.12 (s, 1H); 7.82 (dd, 1H); 7.65 (dd, 1H);

7.61-7.51 (m, 5H); 7.48-7.36 (m, 3H); 2.19 (s, 3H).

MS (El; source 200 =C;70 eV; 200 μΑ): 380 (M+.); 337; 232; 204.

EXAMPLE 97 (R,S)-N-[a-(2-Hydroxyethyl)benzyl]-2-phenyIquinoline-4-carboxamide

0.7 g ί 1.7 mmol! of · R.S)-N-[a-(methoxycarbonylmethyl)benzyl]-2-phenylquinoline64

P30958

AP . Ο Ο 5 7 8

4-carboxamide (compound of Ex. 15.) were dissolved, under nitrogen athmosphere, in 50 ml of r-BuOH and 2 ml of MeOH.

mg (1.6 mmol) of NaBH4 were added in 15 minutes to the boiling solution. The reaction mixture was refluxed for 6 hours, quenched with 5 ml of saturated solution of NH4CI and then evaporated in vacuo to dryness. The residue was dissolved in CH2CI2 and washed with brine; the organic layer was separated, dried over Na2SO4 and evaporated in vacuo to dryness.

The crude product was flash chromatographed on 230-400 mesh silica gel, eluting with Et2O containing 0.5% of cone. XH4OH and then crystallized from ι-PrOH to yield 0.19 g of the title compound.

C25^h22N2<>2

M.P. = 167-169 °C

M.W. = 382.47

Elemental analysis: Calcd. C, 78.52; H, 5.80; N, 7.32;

Found C, 78.49; H, 5.79; N, 7.29.

I.R. (KBr): 3360; 1650; 1592 cm'¹.

300 MHz 1H-NMR (DMSO-d6): 9.30 (d, 1H); 8.31 (d, 2H); 8.13 (d, 1H); 8.10 (s, 1H); 8.03 (d, 1H); 7.81 (dd, 1H); 7.64-7.51 (m, 4H); 7.46 (d, 2H); 7.39 (dd, 2H); 7.29 (dd, 1H); 5.30 (dt, 1H); 4.61 (t, 1H); 3.61-3.41 (m, 2H); 2.11-1.86 (m,2H).

MS (El; source 200 °C;‘70 eV; 200 μΑ): 382 (M+.); 337; 232; 204.

EXAMPLE 98 (S)-N-(a-Ethylbenzyl)-3-(2-dimethylaminoethoxy)'2-phenylquinoline-4carboxamide hydrochloride

0.62 g (1.6 mmol) of (S)-N-(a-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4carboxamide (compound of Ex. 85) were dissolved in 30 ml of dry DMF.

0.58 g (4.0 mmol) of dimethylaminoethylchloride hydrochloride and 0.56 g (4.0 mmol) of K2CO3 were added and the reaction mixture was refluxed for 20 hours.

The K2CO3 was filtered off and the mixture was evaporated in vacuo to dryness, dissolved in AcOEt and washed with H2O and with 20% citric acid. The aqueous layer was made alkaline with 2 N NaOH and extracted with EtOAc; the organic layer was washed with brine, separated, dried over Na2SO4 and evaporated in vacuo to dryness.

The residue was flash chromatographed on 230-400 mesh silica gel, eluting with CH2Cl2/MeOH 98 : 2 containing 0.4% of cone. NH4OH and then with CHoCb/MeOH 86 : 10 containing 0.6% of cone. NH4OH to yield 85 mg of a crude product which was dissolved in EtOAc an J treated with HCI/EaO to obtain 75 mg of ^f s

AP/P/ 9 5 / 0 0 7 4 5

P'i.iMSS ,ν the title compound.

C29H31N3O2.HCI

M.P. = 70 °C dec.

M.W. = 490.05

I.R. (nujol): 3600; 3100; 1650; 1550 cm'k

300 MHz IH-NMR (DMSO-d6): 10.28 (s br, IH); 9.50 (d, IH); 8.10 (d, IH); 7.96 (dd, 2H); 7.78 (m, IH); 7.67-7.61 (m, 2H); 7.617.51 (m, 3H); 7.49-7.39 (m, 4H); 7.33 (dd, IH); 5.08 (dt, IH); 3.90 (t, 2H); 2.96 (dt, 2H); 2.49 (s, 6H); 1.85 (ra, 2H); 0.97 (t, 3H).

MS (FAB POS, thioglycerol matrix, Xe gas, 8 KeV, source 50 °C): 454 (MH+)

EXAMPLE 99 (S)-N-(a-EthylbenzyI)-3-acetylamino-2-phenylquinoline-4-carboxamide

0.40 g (1.05 mmol) of (S)-N-(a-ethylbenzyl)-3-amino-2-phenylquinoline-4carboxamide (compound of Ex. 69) were heated in 25 ml of acetic anhydride at 70 °C for 1 hour and then at 100 °C for additional 3 hours.

The reaction mixture was then evaporated in vacuo to dryness and the residue dissolved in EtOAc; the solution was washed with water, saturated solution of NaHCOj, brine, dried over Na2SO4 and evaporated in vacuo to dryness.

The crude product (0.39 g) was purified by silica gel flash column chromatography, eluting with a mixture of hexane/EtOAc/conc. NH4OH, 70 : 30 : 0.5, respectively, to afford 0.2 g of a pure compound which was recrystallized from acetone to yield 0.14 g of the title compound.

C27H25N3O2

M.P. = 268-269 °C

M.W. = 423.52

Elemental analysis: Calcd. C, 76.57; H, 5.95; N, 9.92;

Found C, 76.38; H, 5.98; N, 9.90.

I.R. (KBr): 3230; 1670; 1640; 1555; 1525 cm’¹.

300 MHz IH-NMR (DMSO-d6); 9.65 (s, IH); 9.05 (d, IH); 8.10 (d, IH); 7.80 (t, IH); 7.70-7.50 (m, 4H); 7.45-7.20 (m, 8H); 5.08 (dt. 1H); 1.85 (m, 2H): 1.60 (s, 3H); 0.97 (t. 3H).

MS (El; source 200 ^:C:70 eV; 200 uA): 423 (M+.); 381: 334: 289; 261; 247; 218.

AP/P/ 95/00745

P3O95S

AP. Ο Ο 5 7 β

EXAMPLE 100 (-)-(S)-N-(a-Ethylbenzyl)-3-(3-diinethylaminopropoxy)-2-phenyIquinoline-4carboxamide hydrochloride

1.2 g (3.1 mmol) of (-)-(S)-N-(a-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4carboxamide (compound of Ex. 85) were dissolved in 15 ml of dry THF.

1.0 g (8.2 mmol) of 3-dimethylaminopropylchloride, dissolved in 10 ml of Et20, L3 g (9.4 mmol) of K2CO3 and 0.16 g of KI were added and the reaction mixture was stined at room temperature for 30 minutes and then refluxed for 2 hours.

Further 0.77 g (6.3 mmol), 1.0 g (8.2 mmol), 0.6 g (4.9 mmol) and additional 0.6 g (4.9 mmol) of 3-dimethylaminopropylchloride, dissolved each time in 10 ml of Et20, and some KI were added every 12 hours and the reaction refluxed.

The K2CO3 was filtered off and the mixture was evaporated in-vacuo to dryness, dissolved in EtOAc and washed with H2O and with 20% citric acid. The aqueous layer was made alkaline with 2 N NaOH and extracted with EtOAc; the organic layer was washed with brine, separated, dried over Na2SO4 and evaporated in-vacuo to dryness.

The residue was flash chromatographed on 230-400 mesh silica gel, eluting with CH2Cl2/MeOH 95: 5 containing 0.5% of cone. NH4OH to yield 0.9 g of a crude product which was dissolved in EtOAc and treated with HCl/Et2O to obtain 0.62 g of the title compound.

C30H33N3O2.HCI

M.P. = 108°C dec.

M.W. = 504.08 [ot]_D2° = -16.0 (c = 0.5, MeOH)

I.R. (KBr): 3400; 3080; 1655; 1545 cm-¹.

300 MHz iH-NMR (DMSO-dg): 5 10.55 (s br, 1H); 9.35 (d, 1H); 8.09 (d, 1H); 7.92 (dd, 2H); 7.76 (ddd, 1H); 7.65-7.51 (ra, 5H); 7.487.40 (m, 4H); 7.31 (dd, 1H); 5.10 (dt, 1H); 3.723.62 (ra, 2H); 2.75-2.60 (m, 2H); 2.58 (d, 3H); 2.56 (d, 3H); 1.90-1.67 (ra, 4H); 1.00 (t, 3H).

MS (El; source 180 °C; 70 V; 200 mA): 467 (M+.); 466; 395; 58.

EXAMPLE 101 (-)-(S)’N-(a-EthylbenzyD-3-[2-(l-phthaIoyl)ethoxy]-2-phenylquinoline-4carboxamide hydrochloride

1.9 0 (5.0 mmol) of (-)-(S)-N-(a-ethylbenzvl)-3-hydroxy-2-phenylquinoline-4carboxamide (compound of Ex. 85, were dissolved in 20 ml of dry THF.

AP/P/ 9 5 / 0 0 7 45

3.8 g ;Τ4.9 mmol) of 2-phthalimidoethylbromide, dissolved in 15 ml of THF, 2.0 g (14.5 mmol) of K2CO3 and 0.25 g of KJ were added and the reaction mixture was stirred at room temperature for 2.5 hours and then refluxed for 2 hours.

1.9 g (7.4 mmol) of 2-phthalimidoethylbromide and some KJ were added and the reaction was refluxed for additional 3.5 hours.

0.5 g (2.0 mmol) of 2-phthalimidoethylbromide and some KJ were added again and the mixture was refluxed for 5 hours.

The K2CO3 was filtered off and the mixture was evaporated in-vacuo to dryness, dissolved in CH2CI2 and washed with H2O. The organic layer was dried over Na2$O4 and evaporated in-vacuo to dryness.

The residue was flash chromatographed on 230-400 mesh silica gel, eluting with hexane/EtOAc 80 : 20 containing 0.5% of cone. NH4OH and then hexane/EtOAc 60 : 40 containing 0.5% of cone. NH4OH to afford 2.6 g of a purified product which was triturated with 1ΡΓ2Ο to yield 2.5 g of the title compound.

^C35^H29^N3°4

M.P. = 172-175°C

M.W. = 555.64 [a]_D ²⁰ = -16.3 (c = 0.5, MeOH)

I.R. (KBr): 3280; 3060; 2960; 1780; 1715; 1660; 1530 cm-1.

300 MHz iH-NMR (DMSO-d₆): δ 9.27 (d, IH); 8.03 (d, IH); 7.92-7.84 (m, 4H);

7.78-7.69 (m, 3H); 7.60-7.53 (m, 2H); 7.46-7.38 (m, 4H); 7.27 (dd, IH); 7.13-7.04 (m, 3H); 4.96 (dt, IH); 3.92-3.78 (ra, 2H); 3.72-3.55 (m, 2H); 1.78 (dq, 2H); 0.93 (t, 3H).

MS (El; source 180 °C; 70 V; 200 mA): 555 (M+.), 526,421, 174.

EXAMPLE 102 (-)-(S)-N-(a-Ethylbenzyl)-3-(2-aminoethoxy>2-phenyIquinoline-4-carboxamide hydrochloride

2.2 g (3.9 mmol) of (-)-(S)-N-(a-ethylbenzyl)-3-[2-(l-phthaloyl)ethoxy]-2-phenyl quinoline-4-carboxamide hydrochloride (compound of Ex. 101) were dissolved in 150 ml of 96% EtOH and 0.38 ml (7.8 mmol) of hydrazine hydrate were added to the boiling solution, which w'as then refluxed for 4 hours.

Further·).d ml '8.2 mmol). 0.2 ml (4.1 mmol), 0.2 ml '4.1 mmol), 0.4 ml (8.2 mmol) and 0.4 ml (8.2 mmol) of hydrazine hydrate were added every 12 hours and the reaction mixture was maintained refluxed.

The reaction mixture was then evaporated in-vacuo to dryness, dissolved in 20 ml HM4. ^\’>Ted and acidified with 10 ml cone. HCI.

AP/P/ 95/00745

OS

AP. Ο Ο 5 7 8

P3O95S

The mixture was boiled for 1 hour arid coded; the phthalydrazide was filtered off.

Tiie aqueous layer was Washed with EtOAc and then made alkaline with 2 N NaOH and extracted with EtOAc; the organic layer was washed with brine, separated, dried O’-er Na2SC4 and evaporated in-vacuo to dryness.

The residue was flash chromatographed on 230-400 mesh silica gel, eluting with HtOAc/MeOH 90 4 containing 1.2% of cone. NH4OH to afford a purified product v hich was dissolved in EtOAc and treated with HCl/Et2O to yield 1.2 g of the title compound.

C-.~H27N3O2.HCI Μ P. - 19^JC dec.

Μ V/. = 4o2.00 ί ι} /-· =- 19.4 (c - 0.5. MeOH)

Lit. (KBr): 3400; 3080; 1640; 1545 cm*¹.

300 MHz iH-NMR (DMSO-d₆): δ 9.45 (d, IH); 8.09 (d, IH); 8.00 (dd. IH): 7.94 (s _w br, 3H); 7.76 (ddd, IH); 7.65-7.51 (m, 4H); 7.48- _r

7.40 (m, 3H); 7.31 (dd, IH); 5.09 (dt, IH); 3.83 (t, _c

2H); 2.72 (m, 2H); 1.93-1.80 (m, 2H); 0.99 (t. 3H). _c

MS (FAB POS, thiogiyceiol matrix; Xs gas, 8 keV; source 50 °C): 426 (MH+).

u

EXAMPLE 103 (+)-(S) N-(a-Ethylbenzyl)-3-(2-(l-pyrroIidinyl)ethoxy]-2-phenylquinoline-4carboxamide hydrochloride

2.0 g (5.2 mmol) of (-)-(S)-N-(a-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4carboxamide (compound of Ex. 85) were dissolved in 25 ml of dry THF.

1.0 g (7-5 nmol) of 2-jyrrolidinoethyl chloride and 2.2g (15.9 nmol) of were added and the reaction mixture was stirred at room temperature for 30 minutes and then refluxed. 1.1 g (8.2 mmol; of 2-pyrrolidinoeLhylchloride were added to the boiling solution which was refluxed overnight.

The K2CO3 was filtered off and the mixture was evaporated in-vacun to dryness, dissolved in EtOAc and washed with f-bO a id 20% citric acid. The aqueous layer

- js made alkaline with 2 N NaOH and extracted with EtOAc; the organic laver was 'v.'-.ivii with !>rmv M-p.r.eed. d; · ' a·· N.i^Oj :ind . · v. le· I 1:/./,, |«>

u/yness.

The residue was flash chromatographed on 230-400 mesh silica gel eluting with

Oof iy/McOH 97: < containin’’ 0.59/ 01 cone. NH4OH to yield !.s e of a purified o' /:. ! ·,' m. ·, di- x.dvcd ui lit <\v 01,-1 7:h H< 9'H 9 > *o vicl i e '1 ,0 Li':C

ΛΠ/Π' n

C31H33N3O2 · HCI

M.P. = 110-115 °C (dec.)

M.W. = 516.08 [a]_D ²⁰ = + 4.5 (c = 0.5, MeOH)

I.R. (KBr): 3400; 3080; 1655; 1545 cm'¹.

300 MHz iH-NMR (DMSO-d₆): δ 10.50 (s br, IH); 9.50 (d, IH); 8.10 (d, IH); 7.96 (dd, 2H); 7.78 (ddd, IH); 7.68-7.30 (m, 10H); 5.10 (dt, IH); 3.90 (m, 2H); 3.20 (m, 2H); 3.00 (m, 2H); 2.65 (m, 2H); 1.95-1.65 (m, 6H); 1.94 (t, 3H).

MS (El; source 180 °C; 70 V; 200 mA): 479 (M+.); 478; 383; 97; 84.

EXAMPLE 104 (-)-(S)-N-(a-EthyIbenzyl)-3-(dime thylami noace tylamino)-2-phenyIquinoline-4carboxamide

1.1 g (2.8 mmol) of (-)-(S)-N-(a-ethylbenzyl)-3-amino-2-phenylquinoline-4carboxamide (compound of Ex. 69) were dissolved, under nitrogen atmosphere, in 10 ml of warm toluene. 0.96 g (5.6 mmol) of chloroacetic anhydride, dissolved in 5 ml of toluene, were dropped and the solution was refluxed for 1 hour.

The reaction mixture was evaporated in-vacuo to dryness, suspended in 10 ml of CH2CI2 and dropped in 5 ml of ice-cooled 28% Me2NH/EtOH.

The solution was stirred at room temperature overnight, then 15 ml of 28% Me2NH/EtOH were added and the reaction mixture was heated at 60 °C in a panapparatus.

The mixture was evaporated in-vacuo to dryness, dissolved in 20% citric acid and washed with EtOAc. The aqueous layer was basified with 2 N NaOH and extracted with EtOAc; the organic layer was washed with brine, separated, dried over Na2SO4 and evaporated in-vacuo to dryness to afford 1.4 g of the crude product

This product was triturated with warm t-P^O to yield 0.86 g of the title compound.

C29^H30^N4°2

M.P. = 189-191 °C

M.W. = 466.59 [a]_D ²⁰ = - 63.1 (c = 0.5, MeOH)

I.R. (KBr): 3230: 3180; 1670: 1630; 1540 cm’¹.

300 MHz iH-NMR (DMSO-d^): δ 9.41 is, IH): 8.97 -d. IH), 8.08 (d, IH); 7.81 (dd, lHi; /.jl·¹-/.?? ιπϊ. -Hi; /.49-/.-6 ini, 8H1; 5.00 (dt, IH); 2.55 (s, 2H); 1.97 (s, 3H); 1.90-1.65 (m, 2H); 0.93 (t, 3H).

MS (El; source 180 °C; 70 V; 200 mA): 466 (M+.): 331: 58.

AP/P/ 9 5/ 00745

P30958

AP . Ο Ο 5 7 8

EXAMPLE 105

N-(a,a-Dimethylbenzyl)-3-hydroxy-2-phenylquinoline-4 carboxamide

2.0 g (7.5 mmol) of 3-hydroxy-2-phenylquinoline-4-carboxylic acid were dissolved, under nitrogen atmosphere, in 70 ml of dry THF and 30 ml of ch₃cn.

1.02 g (7.5 mmol) of cumylamine and 1.12 g (8.3 mmol) of Nhydroxybenzotriazole (HOBT) were added and the reaction mixture was cooled at -10°C.

1.71 g (8.3 mmol) of DCC, dissolved in 20 ml of CH2CI2, were added dropwise and the solution was kept at -5°- 0°C for 2 hours and then at room temperature overnight. The precipitated dicyclohexylurea was filtered off and the solution evaporated in-vacuo to dryness. The residue was dissolved in CH2CI2 and washed with H2O, sat. sol. NaHCO₃, 5% citric acid, sat. sol. NaHCO₃ and brine.

The organic layer was separated, dried over Na2SO4 and evaporated invacuo to dryness; the residue was dissolved in 20 ml of CH2CI2 and left overnight. Some more dicyclohexylurea precipitated and was filtered off. The solution was evaporated in-vacuo to dryness to obtain 1.4 g of a crude product which was flash chromatographed on 230-400 mesh silica gel, eluting initially with hexane/EtOAc 9/1 and then hexane/EtOAc 8/2 to afford 0.4 g of the purified product which was recrystallized twice from iPrOH to yield 0.15 g of the title compound.

^C25^H22^N2°2 \ M.P. = 166-169°C dec.

M.W. = 382.47

I.R. (nujol): 3200; 1650; 1580; 1535 cm-1.

300 MHz 1H-NMR (DMSO-d₆): δ 9.56 (s, IH); 8.92 (s br, IH); 8.00-7.94 (m, 3H); 7.76 (d br, IH); 7.63-7.45 (m, 7H); 7.36 (dd; 2H); 7.24 (dd, IH); 1.72 (s, 6H).

MS (El; source 180 °C; 70 V; 200 mA): 382 (M+.); 264; 247; 219; 119.

EXAMPLE 106

N-(a,a-Dimethylbenzyl)-3-amino-2-phenylquinoline-4-carboxamide

2.0 g (7.6 mmol) of 3-amino-2-phenylquinoline-4-carboxylic acid were dissolved, under nitrogen atmosphere, in 70 ml of dry THF and 30 ml of CH₃CN.

AP/P' 9 ^ri / n 0 7 4 5 ή/λ

1.02 g (7.6 mmol) of cumylamine and 1.12 g (8.3 mmol· of Nhydroxybenzotriazole (HOBT) were added and the reaction mixture was cooled at -10°C.

1.72 g (8.3 mmol) of DCC, dissolved in 20 ml of CH2CI2, were added dropwise and the solution was kept at -5°- 0°C for 2 hours and then at room temperature overnight. The precipitated dicyclohexylurea was filtered off and the solution evaporated in-vacuo to dryness. The residue was dissolved in CH2CI2 and washed with H2O, sat. sol. NaHCO3, 5% citric acid, sat. sol. NaHCO3 and brine.

The organic layer was separated, dried over Na2SO4 and evaporated invacuo to dryness; the residue was dissolved in 20 ml of CH2CI2 and left overnight. Some more dicyclohexylurea precipitated and was filtered off. The solution was evaporated in-vacuo to dryness to obtain 2.0 g of a crude product which was flash chromatographed on 230-400 mesh silica gel, eluting with hexane/EtOAc 6/4 containing 1% of cone. NH4OH to afford 0.9 g of the purified product which was recrystallized from hexanecEtOAc 1/1 and then from i-PrOH to yield 0.45 g of the title compound.

^C25^H23^N3°

M.P. = 166-168°C

M.W. = 381.48

I.R. (nujol): 3460; 3360; 3220; 1667; 1605; 1527 cm-¹.

300 MHz iH-NMR (DMSO-de): δ 9.05 (s, IH); 7.87 (dd, IH); 7.74-7.68 (m, 3H);

7.60-7.42 (m, 7H); 7.37 (dd, 2H); 7.24 (dd, IH); 4.74 (s, 2H); 1.71 (s,6H).

MS (El; source 180 °C; 70 V; 200 mA): 381 (M+.); 263; 218; 119.

EXAMPLE 107 (-)-(S)-N-(a-Ethylbeiizyl)«5-methyl-2-phenylquinolhie-4carboxamide

0.80 g (3.04 mmol) of 5-methyl-2-phenylquinoline-4-carboxylic acid were dissolved, under nitrogen atmosphere, in 30 ml of dry THF and 12 ml of CH3CN.

0.43 g (3.20 mmol) of (S)-(-)-a-ethylbenzylamine and 0.78 g (5.78 mmol) of \-hydroxybenzotriazole (HOBT) were added and the reaction mixture was cooled at -10°C.

0.69 g (3.34 mmol) of DCC, dissolved in 5 ml of CH2CI2, were added dropw’ise and the solution w^Tas kept at -5°- 0°C for 2 hours and then at — -Ί

P3O95*

AP.OG 5 78 room temperature overnight. The precipitated dicyclohexylurea was filtered off and the solution evaporated in-vacuo to dryness. The residue was dissolved in CH2CI2 and washed with H2O, sat. sol. NaHC03, 5% citric acid, sat. sol. NaHC03 and brine.

The organic layer was separated, dried over Na2SC>4 and evaporated invacuo to dryness; the residue was dissolved in 10 ml of CH2CI2 and left overnight. Some more dicyclohexylurea precipitated and was filtered off. The solution was evaporated in-vacuo to dryness to obtain 1.15 g of a crude product which was flash chromatographed on 230-400 mesh silica gel, eluting with hexane/EtOAc 6/2 containing 0.5% of cone. NH4OH to afford 0.47 g of the purified product which was recrystallized from i-Pr2O containing some drops of EtOAc to yield 0.36 g of the title compound as a white powder.

C26H24N2O

M.P. = 189-192 ^CC

M.W. = 380.49 [ajo²⁰ = - 3.8 (c = 0.5, MeOH)

I.R. (KBr); 3280; 3070; 3020; 1635; 1545 cm-1.

300 MHz iH-NMR (DMSO-d₆): δ 9.20 (d, 1H); 8.23 (d, 2H); 7.93 (d, 1H);

7.78 (s, 1H); 7.20-7.70 (m, 10H); 5.00 (dt, 1H); 2.38 (s broad, 3H); 1.70-1.90 (m, 2H); 0.95 (t, 3H).

MS (El; source 180 °C; 70 V; 200 mA): 380 (M+.); 246; 218.

EXAMPLE 108 (R,S)-N-[a-(l-Hydroxyethyl)benzyl]-3-methyl-2-phenylquinoline-4carboxamide

Prepared as described in Ex. 1, starting from 11.08 g ( 39.33 mmol) of crude 3-methyl-2-phenylquinoline-4-carbonylchloride, 4.87 g (32.20 mmol) of l-phenyl-2-hydroxypropylamine and 10.33 ml (74.14 mmol) of TEA in 150 ml of a 1:1 mixture of dry CH2CI2 and CH3CN.

The precipitated TEA hydrochloride was filtered off and the filtrate concentrated in-vacuo to dryness; the residue was dissolved in CH2CI2 (100 ml) and washed with a sat. sol. of NaHCO3, 20 % citric acid and brine. The organic solution was dried over Na2SO4 and evaporated invacuo to dryness to obtain 13.23 g of an oil, which was crystallized from iPrOo (100 ml· containing 6 ml of z-PrOH to yield 9.14 g of the title

AP/P/ 05/00745

P3O95S compound as an off-white solid.

^C26^H24^N2°2

M.P. = 163-165 °C

M.W. = 396.49

I.R. (nujol): 3400; 3260; 1635; 1580 crn'l.

EXAMPLE 109 (R,S)-N-[a-(Methylcarbonyl)benzyl]-3-methyI-2-phenylquinoliiie-4carboxamide

Prepared as described in Example 96, starting from 3.25 g (25.60 mmol) of oxalyl chloride, 3.88 g (49.66 mmol) of DMSO, 8.2 g (20.68 mmol) of (R,S)N-[a-(l-hydroxyethyI)benzyl]-3-methyl-2-phenylquinoline-4-carboxamide (compound of Ex. 108) and 15.72 ml (112.76 mmol) of TEA in 230 ml of dry CH2CI2.

The reaction was quenched with 40 ml of H2O and the organic layer separated and washed with 20% citric acid, sat. sol. NaHCOg and brine. The organic solution was dried over Na2SO4 and evaporated in-vacuo to dryness to afford 9.4 g of the crude title compound as an oil. This residual oil was flash chromatographed on 230-400 mesh silica gel, eluting with a mixture of hexane/ethyl acetate 70 : 30 containing 1% of cone. NH4OH to afford 7.7 g of the purified product which was crystallized from a mixture of EtOAc/hexane 1 : 3 respectively, to yield 6.0 g of the pure title compound.

^C26^H22^N2°2

M.P. = 156-158 °C

M.W. = 394.48

I.R. (nujol): 3270; 3180; 1735; 1725; 1660; 1630; 1527; 1460 cm’¹.

300 MHz iH-NMR (DMSO-d₆): 8 9.53 (d, 1H); 8.01 (d, 1H); 7.73 (dd, 1H);

7.62-7.35 (m, 12H); 5.97 (d, 1H); 2.30 (s br, 3H);

2.18 (s, 3H).

MS (El; source 180 °C; 70 V; 200 mA): 394 (M+.); 352; 351; 246: 218; 217.

EXAMPLE 110 (R,S)-N-[a-(Ethyl)-4-pyridylmethyl]-2-phenylquinoliiie-4carboxamide

AP/P/ 9 5 / 0 0 7 4 5

4.12 g ‘ 16.52 mmol.1 of 2-phenylquinoIine-4-carboxylic acid were dissolved.

P3O95S AP . 0 3 5 7 8 under nitrogen atmosphere, in 40 ml of dry CH2CI2 and 30 ml of THF.

1.50 g (11.01 mmol) of l-(4-pyridyl)-n-propyl amine and 2.23 g (16.52 mmol) of N-hydroxybenzotriazole (HOBT) were added and the reaction mixture was cooled at 0°C.

3.41 g (16.52 mmol) of DCC, dissolved in 26 ml of dry CH2CI2, were added dropwise and the solution was kept at 0°C for 2 hours and then stirred at room temperature for 36 hours. The precipitated dicyclohexylurea was filtered off and the solution evaporated in-vacuo to dryness. The residue was dissolved in 100 ml of CH2CI2 and washed with H2O, 10% K2CO3, 5% citric acid and brine.

The organic layer was separated, dried over Na2SO4 and evaporated invacuo to dryness; the residue was dissolved in 30 ml of CH2CI2 and left overnight. Some more dicyclohexylurea precipitated and was filtered off. The solution was evaporated in-vacuo to dryness to obtain 3.5 g of a crude product which was recrystallized three times from i-PrOH to yield 0.91 g of the title compound.

^24^η21^ν3°

M.P. = 218-219 °C M.W. = 367.45

I.R. (KBr): 3260; 3060; 1648; 1595; 1545; 1350 crn'l.

300 MHz 1H-NMR (DMSO-d₆): 6 9.33 (d, 1H); 8.58 (d, 2H); 8.33 (dd, 2H); 8.15 (d, 1H); 8.14 (s, 1H); 8.03 (d, 1H); 7.82 (dd, 1H); 7.66-7.52 (m, 4H); 7.47 (d, 2H); 5.05 (dt, 1H); 1.85 (dq, 2H); 1.00 (t, 3H).

Ν' MS (El; source 180 °C; 70 V; 200 mA): 367 (M+.); 338; 232; 204.

EXAMPLE 111 (R,S)-N-[<x-(Ethyl)-2-thienylmethyl]-2-phenylquinoline-4carboxamide

1.40 g (8.00 mmol) of l-(2-thienyl)-n-propyl amine hydrochloride and 2.45 ml (17.60 mmol) of TEA were dissolved, under nitrogen atmosphere, in 50 ml of dry CH2CI2 and 30 ml of CH3CN.

2.0 g (8.00 mmol) of 2-phenylquinoline-4-carboxylic acid and 1.30 g (9.60 mmol) of N-hydroxybenzotriazole (HOBT) were added.

2.48 g (12.00 mmol) of DCC, dissolved in 30 ml of dry CH2CI2, were added dropwise and the solution was stirred at room temperature for 36 hours.

N

Ρ V c.'SX ml of 10% HCI were added and the solution stirred for aditional 2 hours. The precipitated dicyclohexylurea was filtered off and the organic layer washed with 10% citric acid and 10% K2CO3.

The organic layer was separated, dried over Na2SC>4 and evaporated invacuo to dryness. The crude product was flash chromatographed on 230400 mesh silica gel, eluting with a mixture of hexane/EtOAc/CH2Cl2 80 : 15 : 0.5 to afford 2.0 g of a yellow oil which was crystallized from a mixture of toluene/hexane to yield 0.9 g of the pure title compound as white crystals.

C23H20N2OS

M.P. = 134-137 °C

M.W. = 372.49

I.R. (KBr): 3230; 3060; 1630; 1590; 1545 cm'¹.

300 MHz iH-NMR (DMSO-d₆): δ 9.33 (d, IH); 8.30 (dd, 2H); 8.15 (d, IH); 8.13 (d, IH); 8.08 (s, IH); 7.84 (ddd, IH); 7.68-7.51 (m.

4H); 7.44 (dd, IH); 7.11 (d, IH); 7.02 (dd, IH);

5.33 (dt, IH); 2.10-1.88 (ra, 2H); 1.05 (t, 3H).

MS (El; source 180 °C; 70 V; 200 mA): 372 (M+.); 343; 232; 204.

G

C

EXAMPLE 112 (+)-(S)-N-(a-Ethylbenzyl)-3-dimethylaminomethyl-2CT phenylquinoline-4-carboxamide hydrochloride ί

5.60 g (21.27 mmol) of 3-,methyl-2-phenylquinoline-4-carboxylic acid were CL dissolved in 100 ml of dichloroethane.

7.60 g (42.50 mmol) of N-bromosuccinimide and 0.52 g (2.00 mmol) of dibenzoyl peroxide were added and the solution refluxed for 24 hours.

The reaction mixture was evaporated in-vacuo to dryness, suspended in 100 ml of 33% Me2NH/EtOH and stirred overnight at room temperature.

The solution was evaporated in-vacuo to dryness, dissolved in 50 ml of 20% K2CO3 and evaporated again in-vacuo to dryness. 50 ml of water were added to the residue and the solution, acidified with 37% HCI, was evaporated in-vacuo to dryness.

The crude residue and 10.8 ml (77.20 mmol) of TEA were dissolved in 50 ml of CH₂C1₂, 50 ml of THF and 100 ml of CH3CN.

3.00 g (22.20 mmol) of (S)-(-)-a-ethylbenzylamine, 0.78 g (5.78 mmol) of Nhydroxybenzotriazole (HOBT) and 11.9 g (57.90 mmol) of DCC were added ar.d the solution was stirred at room temperature overnight.

P3(S? <

AP.00578

The precipitated dicyciohexylurea was filtered off and the organic layer evaporated in-vacuo to dryness.

The brown oily residue was dissolved in 100 ml of CH2CI2 and the precipitate was filtered off. The filtrate was extracted three times with 40% citric acid. The acqueous layer, basified with solid K2CO3, was extracted with CH2CI2; the organic solution dried over Na2SC>4 and evaporated in-vacuo to dryness afforded 10 g of a brown oil.

The crude product was flash chromatographed on 230-400 mesh silica gel, eluting with a mixture of i-Pr2O/CH2Cl2 9 : 1 to afford 2.5 g of a white solid which was dissolved in toluene and left overnight.

The DCU precipitated was filtered and the solution, treated with ethanolic HCl, was evaporated in-vacuo to dryness. The crude product was recrystallized from a mixture of toluene/EtOH to yield 0.7 g of the pure title compound as colourless crystals.

C28H29N3O-HCI

M.P. = 164-167 °C

M.W. = 460.02 [a]_D® = + 25.3 (c = 1, MeOH)

I.R. (KBr): 3440; 3150; 3020; 2560; 2460; 1650; 1540 cm'¹.

300 MHz iH-NMR (DMSO-d₆, 353 K): δ 9.70 (s br, IH); 8.10 (d, IH); 7.85 (dd, IH); 7.80 (s br, IH); 7.70-7.10 (m, 12H); 5.15 (dt, IH); 4.38-4.20 (m, 2H); 2.30 (s,

3H); 2.22 (s, 6H); 2.10-1.82 (m, 2H); 1.00 (t, 3H).

MS (El; source 180 °C; 70 V; 200 mA): 423 (M+.), 380,288.

EXAMPLE 113 (S)-N-(a-Ethylbenzyl)-3-methyl-7-methoxy-2-phenylqumoline-4carboxamide

Prepared as described in Ex. 1, starting from 1.27 g ( 4.09 mmol) of crude 3-methyl-7-methoxy-2-phenylquinoline-4-carbonylchloride, 0.55 g (4.09 mmol) of (S)-(-)-a-ethylbenzylamine and 1.71 ml (12.27 mmol) of TEA in 24 ml of dry CH2CI2 and 1 ml of DMF to help solubility. The reaction mixture was stirred 12 hours at room temperture.

After being concentrated in-vacuo to dryness, the residue was dissolved in CH2CI2 ' 30 ml) and washed with 10% NaHCOg , 5% citric acid and brine. The organic solution was dried over Na2SC>4 and evaporated in-vacuo to dryness to obtain 1.87 g of a crude product, which was flash chromatographed on 230-400 mesh silica gel. eluting with a mixture of

AP/P/ 9 5 / 0 0 7 45

PSiCC-S hexane/EtOAc 70 : 30 to afford 0.350 g of a yellow oil.

^c27^h26ⁿ2°2

M.W. = 410.51

I.R. (KBr): 3240; 2965; 2930; 1635; 1535; 1220 cm-1.

EXAMPLE 114 (S)-N-(a-Ethylbenzyl)-3-amino-5-methyl-2-phenylquinoline-4carboxamide

0.75 g (2.64 mmol) of 3-amino-5-methyl-2-phenylquinoline-4-carboxylic acid were dissolved, under nitrogen atmosphere, in 30 ml of dry THF and 10mlofCH₃CN.

0.38 g (2.83 mmol) of (S)-(-)-a-ethylbenzylamine and 0.69 g (5.18 mmol) of N-hydroxybenzotriazole (HOBT) were added and the reaction mixture was cooled at -10°C.

0.61 g (2.97 mmol) of DCC, dissolved in 5 ml of CH2CI2, were added dropwise and the solution was kept at -5°- 0°C for 2 hours, heated at 50 °C for 4 hours and then left at room temperature overnight.

The precipitated dicyclohexylurea was filtered off and the solution evaporated in-vacuo to dryness. The residue was dissolved in CH2CI2 and — washed with H2O, sat. sol. NaHCO₃, 5% citric acid, sat. sol. NaHCO₃ and brine. cr

The organic layer was separated, dried over Na2SC>4 and evaporated in- Q. vacuo to dryness; the residue was dissolved in 10 ml of CH2CI2 and left overnight. Some more dicyclohexylurea precipitated and was filtered off.

' \ The solution was evaporated in-vacuo to dryness to obtain 0.86 g of a crude product which was flash chromatographed on 230-400 mesh silica gel, eluting with CH2Cl2'^/MeOH/conc. NH4OH, 90 : 10 : 0.5 respectively, to afford 0.41 g of the title compound as an oil.

C26H25N3O M.W. = 395.50

I.R. (KBr): 3480; 3390; 3230; 3020; 1635; 1615; 1545 cm-¹.

EXAMPLE 115 (S)-N-(a-Ethylbenzyb-3-methoxy-5-methyl-2-phenylquinoliue-4carboxamide

1.29 g )4.40 mmol) of 3-methoxy-5-methvl-2-phenylquinoline-4-carboxylic

P3095S

ΑΡ.00578 acid were dissolved, under nitrogen atmosphere, in 40 ml of dry THF and 20 ml of CH3CN.

0.63 g (4.62 mmol) of (S)-(-)-a-ethylbenzylamine and 1.13 g (8.36 mmol) of N-hydroxybenzotriazole (HOBT) were added and the reaction mixture was cooled at -10°C.

1.0 g (4.84 mmol) of DCC, dissolved in 5 ml of CH2CI2, were added dropwise and the solution was kept at -5°- 0°C for 2 hours, heated at 50 °C for 4 hours and then left at room temperature overnight.

The precipitated dicyclohexylurea was filtered off and the solution evaporated in-vacuo to dryness. The residue was dissolved in CH2CI2 and washed with H2O, sat. sol. NaHCO3, 5% citric acid, sat. sol. NaHCO₃ and brine.

The organic layer was separated, dried over Na2SO4 and evaporated invacuo to dryness; the residue was dissolved in 20 ml of CH2CI2 and left overnight. Some more dicyclohexylurea precipitated and was filtered off. The solution was evaporated in-vacuo to dryness to obtain 2.45 g of a crude product which was flash chromatographed on 230-400 mesh silica gel, eluting with hexane/EtOAc 7 : 2 containing 0.5% of cone. NH4OH, to afford 0.28 g of the title compound as an oil.

C27H26N2O2

M.W. = 410.52

I.R. (KBr): 3270; 3020; 1635; 1535 cm’¹.

!> Ί L υ 0 / S 6 ,'d/dV

TABLE 6. Analytical data of compounds of Examples 93-115.

f ree base: mp - 141-143; b free base: [a^²⁰ = - 48.6 (c=0.5,MeOH) u

r-

IMO95X

TABLE 6. (continued)

Claims (17)

1. A compound, or solvate or salt thereof, of formula (I):

5 (I) in which:

Ar is an optionally substituted phenyl, naphthyl or C5.7 cycloalkdienyl group, or an optionally substituted single or fused ring heterocyclic group, having aromatic character, containing from 5 to 12 ring atoms and comprising up to

10 four hetero-atoms in the or each ring selected from S, Ο, N;

R is linear or branched Cj.g alkyl, C3.7 cycloalkyl, C4.7 cycloalkylalkyl, optionally substituted phenyl or phenyl Cj.g alkyl, an optionally substituted five-membered heteroaromatic ring comprising up to four heteroatoms selected from 0 and N, hydroxy Ci_6 alkyl, amino (4.5 alkyl, Cj.g

15 alkylaminoalkyl, di <4.5 alkylaminoalkyl, <4.5 acylaminoalkyl, Cj.g alkoxyalkyl, alkylcarbonyl, carboxy, Cj.g alkoxyxcarbonyl, <4.5 alkoxycarbonyl Cj.g alkyl, aminocarbonyl, (4.5 alkylaminocarbonyl, di Cj. 6 alkylaminocarbonyl, halogeno ¢4.5 alkyl; or is a group -(CH2)p- when cyclized onto Ar, where p is 2 or 3.

20 Rj and R2, which may be the same or different, are independently hydrogen or ¢4.(, linear or branched alkyl, or together form a -(CH2)n- group in which n represents 3,4, or 5; or Rj together with R forms a group -(CH2)q-, in which q is 2, 3,4 or 5.

R3 and R4, which may be the same or different are independently hydrogen, (4.5

25 linear or branched alkyl, C 1.5 alkenyl, aryl, C 1.5 alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, (445 alkoxycarbonyl, trifluoromethyl, acyloxy, phthalimido, amino, mono- and di-Cj.g alkylamino, -O(CH2)_r-NT2. in which r is 2, 3, or 4 and T is hydrogen or C1.5 alkyl or it forms with the adjacent nitrogen a group tr /AP/P/ 9 5 / 0 n 7 &

P>!95X/C in which V and Vj are independently hydrogen or oxygen and u is 0,1 or 2; -O(CH2)_s-OW2 in which s is 2, 3, or 4 and W is hydrogen or Cj.g alkyl; hydroxyalkyl, aminoalkyl, mono-or di-alkylaminoalkyl, acylamino,

5 alkylsulphonylamino, aminoacylamino, mono- or di-alkylaminoacylamino; with up to four R3 substituents being present in the quinoline nucleus; or R4 is a group -(CH2)f when cyclized onto R5 as aryl, in which t is 1,2, or 3;

R₅ is branched or linear Cj.g alkyl, C3.7 cycloalkyl, C4.7 cycloalkylalkyl,

10 optionally substituted aryl, or an optionally substituted single or fused ring heterocyclic group, having aromatic character, containing from 5 to 12 ring atoms and comprising up to four hetero-atoms in the or each ring selected from S, Ο, N;

Xis O, S, orN-CsN.

2. A compound according to claim 1 in which:

Ar is phenyl, optionally substituted by Cpg alkyl or halogen; thienyl or cycloalkdienyl group;

20

3. A compound according to claim 1 or 2 in which:

R is Cj.g alkyl, Cj.g alkoxycarbonyl, Cj_6 alkylcarbonyl or hydroxy Cj.g alkyl.

AP/P/ Q 5 / 0 0 7 A 5

4. A compound according to any one of claims 1 to 3 in which: Rl and R2 are each hydrogen or C j.g alkyl.

5. A compound according to any one of claims 1 to 4 in which: R3 is hydrogen, hydroxy, halogen, Cj.g alkoxy or Cj.g alkyl.

7. A compound according to any one of claims 1 to 6 in which:

6. A compound according to any one of claims 1 to 5 in which:

R4 is hydrogen, alkyl, Cj.g alkoxy, hydroxy, amino, halogen, aminoalkoxy, mono- or di-alkylaminoalkoxy, mono- or di-alkylaminoalkyl, phthaloylalkoxy, mono- or di-alkylaminoacylamino or acylamino;

Ο ²⁰ i'Aiv5\V

R5 is phenyl, thienyl, furyl, pyrryl or thiazolyl.

8. A compound of formula (I) according to claim 1, or a salt or solvate thereof, in which:

Ar is phenyl, 2-chlorophenyl, 2-thienyl or cyclohexadienyl;

R is methyl, ethyl, n-propyl, -COOMe, or -COMe;

Rl and R2 are each hydrogen or methyl;

R3 is hydrogen, methoxy, or hydroxy;

R4 is hydrogen, methyl, ethyl, methoxy, hydroxy, amino, chlorine, bromine, dimethylaminoethoxy, 2-(l-phthaloyl)ethoxy, aminoethoxy, 2-(l-pyrrolidinyl)ethoxy, dimethylaminopropoxy, dimethylaminoacetylamino, acetylamino, or dimethylaminomethyl; R5 is phenyl, 2-thienyl, 2-furyl, 2-pyrryl, 2-thiazolyl or 3-thienyl; and X is oxygen.

9. A compound according to any one of claims 1 to 7, or a salt or solvate thereof, of formula (Ia)

9 y L 0 0 / e 6 /d/dV in which

R, R2, R3 and R4 are as defined for formula (I), in any one of claims 1 to 7 and Y and Z, which may be the same or different, are each Ar as defined for formula (I) in claim 1 or 2.

10. A compound according to claim 9, of formula (lb):

AP.0 0 5 7 8 in which R, R2, R3 and R4, Y and Z are as defined in claim 9.

5

11. A compound according to claim 1 selected from the group consisting of:

C 20 (R,S)-N-(a-methylbenzyl)-2-phenylquinoline-4-carboxamide;

(+)-(S)-N-(a-methylbenzyl)-2-phenylquinoline-4-carboxamide;

(-)-(R)-N-(a-methylbenzyl)-2-phenylquinoline-4-carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-2-phenylquinoline-4 carboxamide;

(+)-(S)-N-[a-(methoxycarbonyl)benzyl]-2-phenylquinoline-4carboxamide;

(-)-(R)-N-[a-(methoxycarbonyl)benzylJ-2-phenylquinoline-4carbox amide ;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-7-methoxy-2-phenylquinoline-4carboxamide;

(R,S)-N- [a-(methoxycarbonyl)benzyl] -7 -hydroxy-2-phenylquinoline-4carboxamide;

(R,S)-N-[a-(carboxy)benzyl]-7-methoxy-2-phenylquinoline-4carboxamide hydrochloride;

(R,S)-N-[a-(methylaminocarbonyl)benzyl]-2-phenylquinoline-4carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-2-(2-thienyl)quinoline-4carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-2-(2-furyl)quinoline-4carboxamide;

(R.S)-N-fa-(methoxycarbonyl !benzyl]-2-(4-pyridyl)quinoline-4carboxamide:

(R,S)-N-[a-(methoxycarbonyl)-2-thienylmethyl]-2-phenylquinoline-4carboxamide;

(R.S)-N-[«-(methoxycarbony!:methyI)benzyl]-2-phenylquinoline-4AP/P/ 9 5 / 0 0 7 45

Ο ²⁵ «<<*>· carboxamide;

(-)-(R)-N-[a-(methoxycarbonyl)-1,4-cyclohexadienylmethyl]-2phenylquinoline-4-carboxamide;

(R,S)-N-[a-(l-hydroxyethyl)benzyl]-2-phenylquinoline-4-carboxamide single diast;

(R,S)-N-(a-ethylbenzyl)-3-methoxy-2-phenylquinoline^4-carboxamide;

(R,S)-N-(a-ethylbenzyl)-3-n-butyl-2-phenylquinoline-4-carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]benzo-l,3-cycloheptadieno[l,2b]quinoIine-8-carboxamide;

(R,S)-N-(a-ethylbenzyl)-3-hexyl-2-phenylquinoline-4-carboxamide;

(-)-(S)-N-(a-ethylbenzyl)-3-methyl-2-phenylquinoline-4-carboxamide;

(+)-(R)-N-(a-ethylbenzyl)-3-methyl-2-phenylquinoline-4-carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-2-(2-methoxyphenyl)quinoline4-carboxamide;

(R,S)-N-(a-ethylbenzyl)-3-phenyl-2-phenylquinoline-4-carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-2-(2-fluorophenyl)quinoline-4carboxamide;

(R,S)-N-[a-(ethyl)-3,4-dichlorobenzyl]-2-phenylquinoline-4carboxamide;

(R,S)-N-[a-(hydroxymethyl)benzyl]-2-phenylquinoline-4-carboxamide;

(R,S)-N-(a-ethylbenzyl)-2-phenylquinoline-4-carboxamide;

(R,S)-N-[oc-(methoxycarbonyI)benzyl]-3-methyl-2-phenylquinoline-4carboxamide;

(R,S)-N-(a-ethylbenzyl)-3-methyl-2-phenylquinoline-4-carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-7-chloro-2-phenylquinoline-4carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-6-methyl-2-phenylquinoline-4carboxamide;

(R,S)-N-[a-(methoxymethyl)benzyl]-2-phenylquinoline-4-carboxannde;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-6-chloro-2-phenylquinoline-4carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-3-ethyl-2-phenylquinoline-4carboxamide;

(R.S !-N-fa-n-propylbenzy’^;-2-f•henylquinoline-d-carboxam: de;

(R,S)-N-(a-ethylbenzyl)-3-ethyl-2-phenylquinoline-4-carboxamide;

(R,S)-N-(a-ethylbenzyl)-3-phthalimido-2-phenylquinoline-4carboxamide;

(R.S )-N-( a-ethyl benzyl )-3-n-propyl-2-phenylquinoline-4-carboxamide;

AP/P/ 9 5 / 0 0 7 A 5

O ²⁵

AP. C 3 518 ‘ (-)-(S)-N-(a-ethylbenzyl)-6-bromo-3-methyl-2-(4bromophenyl)quinoline-4-carboxamide;

(-)-(S)-N-(a-ethylbenzyD-6-bromo-3-methyl-2-phenylquinoline-4carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-6-methoxy-2-phenylquinoline-4carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-2-(2-benzofuryl)quinoline-4carboxamide;

(R,S)-N-[(l,2-diphenyl)ethyl]-2-phenylquinoline-4-carboxamide;

(R,S)-N-(a-trifluoromethylbenzyl)-2-phenylquinoline-4-carboxamide;

(-)-(S)-N-(a-ethyIbenzyl)-3-methoxy-2-phenylquinoline-4-carboxamide;

(-)-(S)-N-(a-ethylbenzyl)-3-ethyl-2-phenylquinoline-4-carboxamide;

(R,S)-N-[a-(ethyl)-4-chlorobenzyl]-2-phenylquinoline-4-carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-N-methyl-2-phenyIquino!ine-4carboxamide;

(R,S)-N-[a-(melhoxycarbonyl)benzyl]-2-(3-thienyl)quinoline-4carboxamide;

(R,S)-N-(a-(methoxycarbonyl)benzyl]-5,6-dihydrobenzo[a]acridine-7carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-2-(2-pyrryl)quinoline-4carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-2-(2-thiazolyl)quinoline-4carboxamide;

(R,S)-N-( 1 -indanyl)-2-phenylquinoline-4-carboxamide;

(R,S)-N-(a-n-butylbenzyl)-2-phenylquinoline-4-carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-2-(4-methylphenyl)quinoline-4carboxamide;

(R,S)-N-(a-heptylbenzyl)-2-phenylquinoline-4-carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-2-(2-methylphenyl)quinoline-4carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-2-(4-methoxyphenyl)quinoline4-carboxamide;

N-(l-phenylcyclopentyl)-2-phenylquinoline-4-carboxamide;

(R.S)-N-[a-(methoxyearbcnyi)benzyl]-2-(4-hydroxyphenyl)quinoline-4carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-2-(3,4methylendioxyphenyl)quinoline-4-carboxamide;

N-(a,a-dimethylbenzyl)-2-phenylquinoline-4-earboxamide;

AP/P/ 9 5 / 0 0 7 45 (R,S)-N-[a-(ethyl)-4-methylbenzyl]-2-phenylquinoline-4-carboxamide;

(R.S)-N-[a-(methoxycarbonyl)benzyl]-2-(3-pyrryl)quinoline-4carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-2-(3,4-dichlorophenyl)quinoline

4-carboxamide;

(-)-(R)-N-[a-(aminomethyl)benzyl]-2-phenylquinoline-4-carboxamide; (-)-(S)-N-(a-ethylbenzyl)-3-amino-2-phenylquinoline-4-carboxamide; (-)-(S)-N-(a-ethylbenzyl)-3-chloro-2-phenylquinoline-4-carboxamide; (-)-(S)-N-(a-ethylbenzyl)-3-bromo-2-phenylquinoline-4-carboxamide; (R,S)-N-(a-wo-propylbenzyl)-2-phenylquinoline-4-carboxamide; (-)-(S)-N-(a-ethylbenzyl)-2-phenylquinoline-4-carboxamide; (+)-(R)-N-(a-ethylbenzyl)-2-phenylquinoline-4-carboxamide; (R,S)-N-[a-(methoxycarbonyl)benzyl]-6-fluoro-2-phenylquinoline-4carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-2-cyclohexylquinoline-4carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-2-(3-chlorophenyl)quinoline-4carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-2-(2-chlorophenyl)quinoline-4carboxamide;

(R,S)-N-(a-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-8-acetyloxy-2-phenylquinoline4-carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-8-hydroxy-2-phenylquinoline-4carboxamide;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-2-(2,4-dichlorophenyl)quinoline4-carboxamide;

(-)-(R)-N-[a-(methoxycarbonyl)-4-hydroxybenzyl]-2-phenylquinoline4-carboxamide hydrochloride;

N-diphenylmethyl-2-phenylquinoline-4-carboxamide;

(-)-(S)-N-(a-ethylbenzyl)-3-hydroxy-2-phenylquinoIine-4-carboxamide;

(+)-(R)-N-(a-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4carboxamide;

i-R)-N-[a-(meihoxycarbonyl) benzyl]-3-hydroxy-2-pheny lquinoline4-carboxamide;

(-)-(R)-N-[a-(dimethylaminomethyl)benzyl]-2-phenylquinoline-4carboxamide;

(R,S)-N-[a-(dimethvlaminocarbonyl)benzyl]-2-phenylquinoline-4SVZ00/56 /d/dV

P30958/C

ΑΡ.00578

Ο ²⁵ carboxamide;

(R,S)-N-[a-(aminocarbonyl)benzyl]-2-phenylquinoline-4-carboxamide;

(R,S)-N-[a-( 1 -pyrrolidinylcarbonyl)benzyl]-2-phenylquinoline-4carboxamide;

(-)-(R)-N-[a-(carboxy)benzyl]-2-phenylquinoline-4-carboxamide hydrochloride;

(R,S)-N-[a-(methoxycarbonyl)benzyl]-2-(4-chlorophenyl)quinoline-4carboxamide;

(R)-N-[a-(methoxycarbonyl)-4-methoxybenzyl]-2-phenylquinoline-4carboxamide;

(R,S)-N-[a-(methoxycarbonyl)-a-(methyl)benzyl]-N-methyl-2phenylquinoline-4-carboxamide hydrochloride;

(R,S)-N-[a-(methylcarbonyl)benzyl]-2-phenylquinoline-4-carboxamide;

(R,S)-N-[a-(2-hydroxyethyl)benzyl]-2-phenylquinoline-4-carboxamide;

(-)-(S)-N-(a-ethylbenzyl)-3-(2-dimethylaminoethoxy)-2phenylquinoline-4-carboxamide hydrochloride; (-)-(S)-N-(<x-ethylbenzyl)-3-acetylamino-2-phenylquinoline-4carboxamide;

(-)-(S)-N-(a-ethylbenzyl)-3-(3-dimethylaminopropoxy)-2phenylquinoline-4-carboxamide hydrochloride;

(-)-(S)-N-(a-ethylbenzyl)-3-i2-( 1 -phthaloyl)ethoxy]-2-phenylquinoline4-carboxamide hydrochloride;

(-)-(S)-N-(a-ethylbenzyl)-3-(2-aminoethoxy)-2-phenylquinoline-4carboxamide hydrochloride;

(+)-(S)-N-(a-ethylbenzyl)-3-[2-(l-pyrrolidinyl)ethoxy]-2phenylquinoline-4-carboxamide hydrochloride;

(-)-(S)-N-(a-ethylbenzyl)-3-(dimethyIaminoacetylamino)-2phenylquinoline-4-carboxamide;

N-(a,a-dimethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide;

N-(a,a-dimethylbenzyl)-3-amino-2-phenylquinoline-4-carboxamide;

(-)-(S)-N-(a-ethylbenzyl)-5-methyI-2-phenylquinoline-4-carboxamide;

(R,S)-N-[a-(l-hydroxvethyl)benzyl]-3-methyl-2-phenylquinoline-4carboxamide;

(R,S)-N-[a-(methylca.'bonyl.ibenzyi]-3-methyl-2-phenylquinoiine-4carboxamide;

(R,S)-N-[a-(ethyl)-4-pyridylmethyl]-2-phenylquinoline-4-carboxamide;

(R,S)-N-[a-(ethyl)-2-thienyIrnethyl]-2-phenyIquinoline-4-carboxamide;

(+)-(S)-N-(a-ethylbenzyl)’3-dimethyiaminomethyl-2-phenyiquinolineAP/P' Q 5 / Γ, 0 7 ί 5 (S)-N-(a-ethylbenzyl)-3-methyl-7-methoxy-2-phenylquinoline-4carboxamide;

i¹5> rc λ ί

4-carboxamide hydrochloride;

(S)-N-(oc-ethylbenzyl)-3-amino-5-methyl-2-phenylquinoline-4carboxamide;

(S)-N-(a-ethylbenzyl)-3-methoxy-5-methyl-2-phenylquinoline-4carboxamide:

12. A compound according to claim 1 substantially as hereinbefore described 10 with reference to any one of the Examples.

13. A process for preparing a compound of formula (I) as defined in any one of claims 1 to 12, or a solvate or salt thereof which comprises reacting a compound of formula (ΠΙ)

R* (ΠΙ) in which R', R’j, R'2 and Ar' are R, Rp R2 and Ar as defined for formula (I) or a group or atom convertible to R, Rj, R2 and Ar, with a compound of

20 formula (Π)

Υ' ΠΗ

R'.

AP/P/ 95/00745 (Π) or an active derivative thereof, in which R’3, R'4, R'5 and X' are R3, R4, 25 R5 and X as defined for formula (I) or a group convertible to R3, R4, R5 and X, to form a compound of formula (lc) i-5095.-,-C

AP. 0 0 5 78

X’

R’ (Ic) and optionally thereafter performing one or more of the following steps:

(a) where R’, R’j to RX, Ar' and X' are other than R. Rj to R5, Ar and X. vonvert-ng any one of R', R'j to R'5, Ar' and X' to R, Rj to R5, Ar and X to oi uiin a compound of formula (I), (b) where R', R'j to R'5, Ar' and X’ are R, Rj to R5, Ar and X, converting any -one of R, Rj 10 R5, Ar and X to another R, Rj to R5, Ar and X. to obtain a compound of formula (I),

19 (c) forming a salt and/or solvate of the obtained compound of formula (Ic).

!4 A process according to claim 13 in which the active derivative of the compound of formula (Π) is an acid halide.

15. A pharmaceutical composition comprising a compound of formula (I) or salt or solvate thereof, as defined in any one of claims 1 to 12, and a pharmaceutically acceptable carrier.

16. A compound of formula (I), or a solvate or salt thereof, as defined in any one of claims 1 to 12, for use as an active therapeutic substance.

AP/P/9 5 / 0 0 7 65 i 7. A compound of formula (I), or a solvate or salt thereof, as defined in anyone of claims I to 12, for use in treating pulmonary disorders (asthma, chronic

25 obstructive pulmonary diseases -COPD-, airway hyperreactivity, cough), skin disorders and itch (for example, atopic dermatitis and cutaneous wheal and flare), neurogenic inflammation and CNS disorders (Parkinson's disease, movement disorders, society asid psychosis), convulsive disorders, epilepsy, renal disorders, urinarv ‘lenminence. ocular inflammation, inflammatory pain, eating disorders (food intake inhibition), allergic rhinitis, neurodegenerative disorders (for example .Zi.jiu.ci s disease), psoriasis. Huntington's disease, and depression.

18. An NK3 receptor antagonist for use in the treatment of convuls.ve d-<orders. epilepsy, renal disorders, urinary incontinence, ocular inflammation, ntummatoiy pain, eating disorders (food intake inhibition), allergic rhinitis, ο ·;·.···Ηίο;!.·ι.οΐ4ΐϊνο d^:.soi tiers , i'c>r '-xample Ai/heimt r'.s disease), p.sorusis.

1t Use of a compound of formula (I), or a solvate or salt thereof, as defined m any one of claims 1 to 12 in the manufacture of a medicament for use in the treatment of pulmonary disorders (asthma, chronic obstructive pulmonary

5 diseases -COPD-, airway hyperreactivity, cough), skin disorders and itch ffor example, atopic dermatitis and cutaneous wheal and flare), neurogenic inflammation and CNS disorders (Parkinson's disease, movement disorders, convulsive disorders, epilepsy, renal disorders, urinary incontinence, ocular inflammation, inflammatory pain, eating disorders (food intake inhibition), id .ilVrgic rhinitis, neurodegenerative disorders (for example Alzheimer's disease), ns·, nas Huntington's disease, and depression.

Use of an NK3 receptor antagonist in the manufacture of a medicament for use in Uk treatment of convulsive disorders, epilepsy, renal disorders, urinary

15 incontinence, ocular inflammation, inflammatory pain, eating disorders (food • ,‘akc inhibition), allergic rhinitis, neurodegenerative disorders (for example ^u

Alzheimer's disease), psoriasis, Huntington's disease, and depression. * r

21. A method for the treatment and/or prophylaxis of pulmonary disorders tastiima, chronic obstructive pulmonary diseases -COPD-, airway hyperreactivity, cough), skin disorders and itch (for example, atopic dermatitis and cutaneous wheal and flare), neurogenic inflammation and CNS disorders (Parkinson's disease, movement aisorders, anxiety and psychosis),convulsive disorders, epilepsy, renal disorders, urinary incontinence, ocular inflammation, inflammatory pain, eating '5 disorders (food intake inhibition), allergic rhinitis, neurodegenerative disorders (for example Alzheimer’s disease), psoriasis, Huntington's disease, and depression in mammals, which comprises administering to the mammal in need of such ' ·’ treatment and/or prophylaxis an effective amount of a compound of formula (1),

O’- a .solvate or salt thereof, as defined in claim 1.

I .

22. A method for the treatment and/or prophylaxis of convulsive disorders, epilepsy, renal disorders, urinary incontinence, ocular inflammation, inflammatory pain, eating disorders (food intake inhibition), allergic rhinitis, neurodegenerative disorders (for example Alzheimer's disease), psoriasis,

35 Huntington's disease, and depression in mammals, which comprises administering u the mammal in need of such treatment and/or prophylaxis an effective amount of an receptor antagonist.